<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Cardiol Rev</journal-id><journal-id journal-id-type="publisher-id">CCR</journal-id><journal-title-group><journal-title>Current Cardiology Reviews</journal-title></journal-title-group><issn pub-type="ppub">1573-403X</issn><issn pub-type="epub">1875-6557</issn><publisher><publisher-name>Bentham Science Publishers Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20676279</article-id><article-id pub-id-type="pmc">2822143</article-id><article-id pub-id-type="publisher-id">CCR-5-203</article-id><article-id pub-id-type="doi">10.2174/157340309788970306</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The GH/IGF-1 Axis and Heart Failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Castellano</surname><given-names>Graziella</given-names></name></contrib><contrib contrib-type="author"><name><surname>Affuso</surname><given-names>Flora</given-names></name></contrib><contrib contrib-type="author"><name><surname>Conza</surname><given-names>Pasquale Di</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fazio</surname><given-names>Serafino</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff">Department of Internal Medicine, School of Medicine, University of Naples &#x0201c;Federico II&#x0201d;, Naples, Italy</aff><author-notes><corresp id="cor1"><label>*</label>Address for correspondence to this author at the Department of Internal Medicine. University of Naples &#x0201c;Federico II&#x0201d;, <italic>Via</italic> S. Pansini 5, 80131 Naples, Italy; Tel: +39 (0) 81 7463737; Fax: +39 (0)81 7463737; E-mail: <email xlink:href="fazio@unina.it">fazio@unina.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2009</year></pub-date><volume>5</volume><issue>3</issue><fpage>203</fpage><lpage>215</lpage><history><date date-type="received"><day>7</day><month>7</month><year>2008</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 Bentham Science Publishers Ltd.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis regulates cardiac growth, stimulates myocardial contractility and influences the vascular system. The GH/IGF-1 axis controls intrinsic cardiac contractility by enhancing the intracellular calcium availability and regulating expression of contractile proteins; stimulates cardiac growth, by increasing protein synthesis; modifies systemic vascular resistance, by activating the nitric oxide system and regulating non-endothelial-dependent actions. The relationship between the GH/IGF-1 axis and the cardiovascular system has been extensively demonstrated in numerous experimental studies and confirmed by the cardiac derangements secondary to both GH excess and deficiency. Several years ago, a clinical non-blinded study showed, in seven patients with idiopathic dilated cardiomyopathy and chronic heart failure (CHF), a significant improvement in cardiac function and structure after three months of treatment with recombinant GH plus standard therapy for heart failure. More recent studies, including a small double-blind placebo-controlled study on GH effects on exercise tolerance and cardiopulmonary performance, have shown that GH benefits patients with CHF secondary to both ischemic and idiopathic dilated cardiomyopathy. However, conflicting results emerge from other placebo-controlled trials. These discordant findings may be explained by the degree of CHF-associated GH resistance. In conclusion, we believe that more clinical and experimental studies are necessary to exactly understand the mechanisms that determine the variable sensitivity to GH and its positive effects in the failing heart.</p></abstract><kwd-group><title>Keywords</title><kwd>GH/IGF-1 axis</kwd><kwd>Chronic heart failure</kwd><kwd>Acromegaly</kwd><kwd>GH deficiency.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Growth hormone (GH), a 191 amino acid single-chain peptide, is synthesized and secreted by the somatotroph cells of the anterior pituitary gland [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>]. Its secretion is strictly regulated by two hypothalamic neurohormones: GH releasing factor (GHRF) and GH inhibiting factor (somatostatin). The ratio between these two factors represents the mechanism by which neurologic and extra-neurologic influences may functionally affect GH release [<xref ref-type="bibr" rid="R2">2</xref>-<xref ref-type="bibr" rid="R9">9</xref>]. Furthermore, GH can modulate its own secretion by different feedback loops: indirectly by producing insulin-like growth factor-1 (IGF-1), which inhibits somatotroph cells and stimulates somatostatin release, or directly by inhibiting GHRF messenger RNA (mRNA) and by stimulating somatostatin mRNA synthesis [<xref ref-type="bibr" rid="R10">10</xref>].</p><p>GH secretion is pulsatile, and is regulated by a number of neurologic, metabolic and hormonal influences: during most of the day, the plasma GH level of adults is 5 ng/ml, with one or two sharp spikes three to four hours after meals. The lowest circulating level is early in the morning and highest about one hour after the onset of deep sleep [<xref ref-type="bibr" rid="R11">11</xref>-<xref ref-type="bibr" rid="R14">14</xref>]. Secretion is enhanced by &#x003b1;<sub>2</sub> agonists, hypoglycemia and daily life stresses, and inhibited by &#x003b2; and &#x003b1;<sub>1</sub> agonists, glucocorticoids and aging [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R14">14</xref>-<xref ref-type="bibr" rid="R17">17</xref>].</p><p>The biological effects of GH are mediated by the interaction with a specific receptor (GHR), a single chain trans-membrane protein, expressed in almost all cellular types (liver membranes, adipocytes, fibroblasts, lymphocytes, myocytes) [<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R18">18</xref>, <xref ref-type="bibr" rid="R19"> 19</xref>]. Its dimerization activates the Jak/Stat pathway (Janus Kinase and Signaling Transducer and Activates of Transcription), which induces intracellular signal transduction, thereby altering calcium (Ca<sup>2+</sup>) trafficking, regulating expression of contractile and cytoskeletal proteins and modifying activation of intrinsic neurohormonal networks [<xref ref-type="bibr" rid="R20">20</xref>].</p><p>GH exerts its effects either directly or indirectly [<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R22">22</xref>]. Most of the indirect effects are mediated by induction of IGF-1 expression in the liver and in peripheral tissues [<xref ref-type="bibr" rid="R23">23</xref>-<xref ref-type="bibr" rid="R27">27</xref>]. It is well known that IGF-1 is the principal, but not the only, GH mediator. For instance, GH stimulates induction of c-myc proto-oncogene in various tissues and of platelet-derived growth factor in the heart [<xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R29"> 29</xref>]. But the role of these and other growth factors is still unknown.</p><p>IGF-1, a 70 amino acid single chain protein, structurally homologous to pro-insulin, is synthesized in liver and kidney, although the local production in other tissues appears to be important in mediating, by paracrine or autocrine mechanisms, GH anabolic and growth-promoting effects [<xref ref-type="bibr" rid="R30">30</xref>-<xref ref-type="bibr" rid="R33">33</xref>]. IGF-1 circulates bound to protein carriers (IGFBPs), which serve not only to transport IGF-1 in the circulation but also to prolong its half life, modulate its tissue specificity and strengthen or neutralize its biological actions [<xref ref-type="bibr" rid="R31">31</xref>]. The serum concentration of IGFBPs is influenced by circulating GH levels, but does not have a circadian pattern. The intracellular signal pathways involved in IGF-1 transduction implicate insulin receptor substrate (IRS)-1, phosphatidylinositol (PI) 3-kinase, phospholipase C (PLC)-g1, mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) cascade [<xref ref-type="bibr" rid="R34">34</xref>].</p><p>The diminished age-related amplitude of GH pulses and the increased resistance to GH action contribute to reduce IGF-1 plasma concentration. The mechanisms underlying these age-related modifications include peripheral influences (gonadal steroids, adiposity), changes in hypotalamic neuropeptides and neurotransmitters, and increase in somatostatin secrection. [<xref ref-type="bibr" rid="R35">35</xref>]. Although the decline of GH/IGF-1 axis is associated with an increase in GH/IGF-1 receptors on cardiomyocytes, this increase fails to compensate the reduction of GH secretion probably because of the diminished intracellular signal transduction [<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R37">37</xref>]. In fact, in rodents, it has been widely demonstrated that with aging there is a reduction of JAK2 phosphorilation, a decline of MAP kinase activity, a reduction of STAT3 activation and a decrease in nuclear translocation [<xref ref-type="bibr" rid="R37">37</xref>-<xref ref-type="bibr" rid="R40">40</xref>]. GH/IGF-1 deficiency contributes to physiological age-related cardiovascular modifications, such as decrease in the number of cardiomyocytes [<xref ref-type="bibr" rid="R41">41</xref>-<xref ref-type="bibr" rid="R43">43</xref>], rarefaction of coronary arterioles [<xref ref-type="bibr" rid="R44">44</xref>], increase in fibrosis and collagen deposition [<xref ref-type="bibr" rid="R45">45</xref>-<xref ref-type="bibr" rid="R48">48</xref>], reduced protein synthesis [<xref ref-type="bibr" rid="R49">49</xref>] and alteration of contractile proteins with reduction in myosin-actin bridges [<xref ref-type="bibr" rid="R50">50</xref>].</p></sec><sec><title>PHYSIOLOGICAL EFFECTS OF GH</title><p>GH alters body&#x02019;s homeostasis and its effects can generally be described as anabolic. GH directly stimulates chondrocyte division and multiplication; it increases calcium retention, thereby strengthening bone mineralization [<xref ref-type="bibr" rid="R51">51</xref>]; promotes lipolysis and protein synthesis, by stimulating amino acid uptake [<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R52">52</xref>-<xref ref-type="bibr" rid="R55">55</xref>]; induces hyperglycemia, consequent to insulin resistance and gluconeogenesis [<xref ref-type="bibr" rid="R52">52</xref>,<xref ref-type="bibr" rid="R56"> 56</xref>]; increases muscle mass, through sarcomere hyperplasia, and stimulates the immune system. In addition, GH increases peripheral conversion of thyroid hormone thyroxine (T4) to triiodothyronine, with a consequent decline of thyroid stimulating hormone and T4 levels [<xref ref-type="bibr" rid="R57">57</xref>]. It also activates the renin-angiotensin-aldosterone system and decreases atrial natriuretic peptide circulating level [<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R59">59</xref>].</p></sec><sec><title>CARDIOVASCULAR EFFECTS</title><p>Besides growth promoting and metabolic effects, the GH/IGF-1 axis regulates cardiac growth, stimulates myocardial contractility and influences the vascular system (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>).</p><p>The myocardium and the endothelium not only express receptors for both GH and IGF-1, but also produce IGF-1 locally. Thus, there is a direct action of GH by endocrine mechanism and/or indirect action by autocrine/paracrine mechanisms of IGF-1 [<xref ref-type="bibr" rid="R30">30</xref>-<xref ref-type="bibr" rid="R32">32</xref>]. On vascular system, the GH/IGF-1 axis exerts its effects by activating the nitric oxide (NO) system and regulating non-endothelial-dependent actions [<xref ref-type="bibr" rid="R60">60</xref>-<xref ref-type="bibr" rid="R69">69</xref>]. NO production relaxes arterial smooth muscle cells, thereby reducing vascular tone. Furthermore, NO inhibits proliferation and migration of smooth muscle cells, reduces platelet adhesion, decreases lipoxygenase activity and oxidized LDL-cholesterol [<xref ref-type="bibr" rid="R60">60</xref>-<xref ref-type="bibr" rid="R69">69</xref>]. Recently, NO has been shown to modulate cardiac cytoskeletal functions by altering calcium myofilament responsiveness [<xref ref-type="bibr" rid="R70">70</xref>]. In addition, IGF-1 may cause vasorelaxation both by enhancing Na<sup>+</sup>/K<sup>+</sup> ATPase activity [<xref ref-type="bibr" rid="R71">71</xref>] and regulating gene expression of K<sub>ATP</sub> channel in vascular smooth cells [<xref ref-type="bibr" rid="R72">72</xref>]. This ATP-sensitive potassium channel consists of two subunits: the sulfonylurea receptor and the inwardly rectifying potassium channel, which could be critical in regulating vascular tone [<xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R74">74</xref>].</p><p>The GH/IGF-1 axis may also regulate cardiac growth and metabolism, by increasing amino acid uptake, protein synthesis, cardiomyocyte size and muscle-specific gene expression. Specifically IGF-1 promotes cardiac hypertrophy and increases muscle specific gene transcription (namely, troponin I, myosin light chain-2, and &#x003b1;-actin) [<xref ref-type="bibr" rid="R75">75</xref>-<xref ref-type="bibr" rid="R77">77</xref>]. Moreover, IGF-1 promotes collagen synthesis by fibroblasts, whereas GH increases the collagen deposition rate in the heart [<xref ref-type="bibr" rid="R78">78</xref>-<xref ref-type="bibr" rid="R81">81</xref>]. Substantial evidence indicates that IGF-1 influences the trophic status of myocardium by reducing apoptosis of cardiomyocytes, thus preventing myocyte loss [<xref ref-type="bibr" rid="R76">76</xref>, <xref ref-type="bibr" rid="R82">82</xref>].</p><p>The GH/IGF-1 axis can also control intrinsic cardiac contractility through different mechanisms: by enhancing myofilament calcium sensitivity [<xref ref-type="bibr" rid="R76">76</xref>, <xref ref-type="bibr" rid="R77">77</xref>, <xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R83">83</xref>], modifying intracellular calcium transient through an increase in L- type calcium channel activity [<xref ref-type="bibr" rid="R84">84</xref>, <xref ref-type="bibr" rid="R85">85</xref>] and up-regulating sarcoplasmatic reticulum ATPase (SERCA) levels [<xref ref-type="bibr" rid="R86">86</xref>, <xref ref-type="bibr" rid="R87">87</xref>]. SERCA up-regulation may cause an increase in contractility, enhancing calcium contractile reserve in the sarcoplasmatic reticulum and allowing a higher calcium peak level on stimulation.</p><p>While IGF-1 positively affects cardiac contractility, GH physiological role, although GHRs are expressed on the heart, probably does not include acute modulation of myocardial contractility, but it needs to mediate some other functions such as protein synthesis or local IGF-1 production [<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R88">88</xref>].</p><p>Moreover, GH induces myosin phenoconversion toward the low ATPase activity V3 isoform. The prevalence of V3 isoform increases the number of actin-myosin cross-bridges and their attachment time, enhances protein calcium sensitivity and calcium availability and allows the myocardium to function at lower energy cost [<xref ref-type="bibr" rid="R76">76</xref>, <xref ref-type="bibr" rid="R77">77</xref>]. V3 isoform also prevails in pathologic cardiac hypertrophy secondary to hemodynamic overload, to compensate depressed contractility and high wall stress.</p><p>Although GH reduces energy output, it favours the conversion of metabolic energy to external work and enhances the intrinsic ability of the myofilament to develop force, resulting in an improvement of LV performance [<xref ref-type="bibr" rid="R89">89</xref>]. In conclusion, GH improves myocardial energy metabolism reducing oxygen consumption and energy demand, even in failing heart in which the increment in wall stress increases oxygen demand [<xref ref-type="bibr" rid="R90">90</xref>]</p><p>The relationship between the GH/IGF-1 axis and the cardiovascular system has been extensively demonstrated in numerous experimental studies and confirmed by the derangements of cardiac structure and function reported in patients with both GH excess (acromegaly) and GH deficiency (GHD).</p></sec><sec><title>CLINICAL EVIDENCE OF GH EXCESS IN HUMANS</title><p>Acromegaly is a clinical condition consequent to chronic GH excess that affects the heart. Acromegalic cardiac involvement was first described by Huchard in 1895 [<xref ref-type="bibr" rid="R91">91</xref>]. Subsequent reports documented that chronic GH excess leads to cardiac functional and morphological abnormalities [<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R76">76</xref>, <xref ref-type="bibr" rid="R77">77</xref>, <xref ref-type="bibr" rid="R92">92</xref>-<xref ref-type="bibr" rid="R97">97</xref>].</p><p>Acromegalic cardiomyopathy can be divided into three main stages [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R89">89</xref>]. The early stage is characterized by functional abnormalities: enhanced myocardial contractility, decreased peripheral vascular resistance and increased cardiac output (hyperkinetic state) [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R89">89</xref>, <xref ref-type="bibr" rid="R98">98</xref>, <xref ref-type="bibr" rid="R99">99</xref>]. In stage 1, ventricular wall thickening is not associated with cavity dilatation, so that relative wall thickness (left ventricular [LV] wall thickness/LV radius) increases and causes a reduction in wall stress and an increase in cardiac performance, according to the Laplace&#x02019;s law (wall stress=LV pressure/LV relative wall thickness) [<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R89">89</xref>, <xref ref-type="bibr" rid="R99">99</xref>-<xref ref-type="bibr" rid="R106">106</xref>]. In this stage, the reduction of wall stress together with the positive effects of GH/IGF-1 on myocardial contractility and systemic vascular resistance produces an improvement in cardiac function. Initially, this increase in wall thickness and LV mass has no negative impact on diastolic function [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R99">99</xref>, <xref ref-type="bibr" rid="R105">105</xref>]. The intermediate stage (after about five years of active disease) is characterized by biventricular hypertrophy, diastolic dysfunction and impaired cardiac performance, which are undetected under resting condition, but appear on effort [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R89">89</xref>, <xref ref-type="bibr" rid="R103">103</xref>, <xref ref-type="bibr" rid="R104">104</xref>, <xref ref-type="bibr" rid="R107">107</xref>-<xref ref-type="bibr" rid="R109">109</xref>]. Hypertrophy, which entails proliferation of myocardial fibrous tissue, leads to progressive interstitial remodelling, which causes inexorable deterioration of cardiac performance. Diastolic abnormallities, which usually anticipate systolic dysfunction, include prolonged isovolumic relaxation time, decreased early-to-late mitral and tricuspid velocity ratio, reduced diastolic filling wave and increased reversal flow during atrial contraction. These alterations result in impaired ventricular relaxation and enhanced ventricular stiffness [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R104">104</xref>, <xref ref-type="bibr" rid="R106">106</xref>]. In a very late stage, acromegalic cardiomyopathy is characterized by systolic and diastolic dysfunction that can lead to congestive heart failure, often resistant to conventional therapies, increased myocardial mass, marked ventricular cavity dilatation and high peripheral vascular resistance [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R98">98</xref>]. It also includes cardiac valve disease (mitral and aortic valve regurgitation), coronary artery disease and arrhythmias [<xref ref-type="bibr" rid="R110">110</xref>]. The prevalence of these complications is likely to depend on the duration of GH excess. Myocardial hypertrophy and interstitial fibrosis, which increase as the disease progresses, are responsible for myocardial ischemia, consequent to reduced capillary density, and arrhythmias, due to the interference of the pulse propagation process in the myocardium [<xref ref-type="bibr" rid="R111">111</xref>]. Electrocardiographic recordings have demonstrated a higher frequency of ectopic beats, paroxysmal atrial fibrillation or supraventricular tachycardia, sick sinus syndrome, ventricular tachycardia and bundle branch block in acromegalic patients as compared with the normal population [<xref ref-type="bibr" rid="R112">112</xref>-<xref ref-type="bibr" rid="R114">114</xref>].</p><p>The most relevant histological abnormalities are interstitial fibrosis, reduced capillary density, increased extracellular collagen deposition, myofibrillar derangement, lymphomononuclear infiltration and myocyte death due to necrosis and apoptosis [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R110">110</xref>, <xref ref-type="bibr" rid="R115">115</xref>, <xref ref-type="bibr" rid="R116">116</xref>].</p><p>GH excess seems to exert different and potentially opposite effects on the heart: it enhances cardiac performance in early-stage acromegaly, whereas it causes cardiac dysfunction in the intermediate-late phase. This apparent discrepancy is easily clarified: a physiological GH level or short-term excess exert positive inotropic effect, whereas by causing morphological and functional adaptive changes, long-term exposure to GH excess induces cardiac dysfunction and progression to heart failure [<xref ref-type="bibr" rid="R76">76</xref>, <xref ref-type="bibr" rid="R77">77</xref>, <xref ref-type="bibr" rid="R92">92</xref>, <xref ref-type="bibr" rid="R98">98</xref>, <xref ref-type="bibr" rid="R106">106</xref>, <xref ref-type="bibr" rid="R117">117</xref>, <xref ref-type="bibr" rid="R118">118</xref>].</p><p>GH/IGF-1 may cause acromegalic morphological and functional changes either directly by affecting myocyte growth and contractility, or indirectly by affecting peripheral vascular resistance, modifying extracellular volume and neurohormonal activity. Subsequently, with the increase of arterial stiffness due to hypertrophy and fibrosis of the arterial muscular tunica, about 20-50% of acromegalic patients become hypertensive [<xref ref-type="bibr" rid="R119">119</xref>]. Experimental studies about the role of the neurohormonal system in the development and progression of acromegalic cardiomyopathy, have produced conflicting results [<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R120">120</xref>-<xref ref-type="bibr" rid="R128">128</xref>]. In the late 1970s, it was reported that chronic GH excess, by eliciting sympathetic overactivity, induces myocardial hypertrophy [<xref ref-type="bibr" rid="R120">120</xref>]. Only two decades later, it was demonstrated that GH exerts no sympatho-excitatory effects [<xref ref-type="bibr" rid="R122">122</xref>, <xref ref-type="bibr" rid="R129">129</xref>]. Recently, it has been shown that in acromegalic cardiomyopathy, in contrast with other conditions of cardiac hypertrophy, there are low B-type natriuretic peptide (BNP) circulating levels and that the normalization of GH/IGF-1 serum concentrations is followed by an increase in BNP levels [<xref ref-type="bibr" rid="R130">130</xref>].</p><p>There is compelling evidence that IGF-1 is involved in the intricate cascade of events leading to cardiac hypertrophy. In fact, in response to pressure or volume overload, IGF-1 expression increases in parallel to hypertrophy [<xref ref-type="bibr" rid="R131">131</xref>, <xref ref-type="bibr" rid="R132">132</xref>]. Moreover, numerous trials have shown that GH suppression, associated with IGF-1 normalization, reduces cardiovascular mortality to that of general population, which supports the concept that cardiac alterations in acromegaly are strictly related to GH/IGF-1 excess [<xref ref-type="bibr" rid="R104">104</xref>,<xref ref-type="bibr" rid="R133">133</xref>-<xref ref-type="bibr" rid="R141">141</xref>]. By normalizing serum GH and IGF-1 values, somatostatin analogues improve diastolic filling parameters (ventricular isovolumic relaxation and early diastolic filling velocity), reduce volume overload and pulmonary and wedge pressures, and enhance cardiac performance [<xref ref-type="bibr" rid="R137">137</xref>, <xref ref-type="bibr" rid="R142">142</xref>, <xref ref-type="bibr" rid="R143"> 143</xref>]. Data on the effectiveness of acromegalic treatment are still conflicting as regards the effects on ventricular hypertrophy. Some studies demonstrate that treatment can reduce LV mass to a normal value [<xref ref-type="bibr" rid="R105">105</xref>], whereas others show no significant change or only a small improvement in LV mass [<xref ref-type="bibr" rid="R144">144</xref>]. Although it is not yet known whether the acromegalic heart can return to normal condition, the experimental data available indicate that cardiac hypertrophy is reversible and that the reversal may be complete if GH activity is restored to normal level for a sufficient amount of time [<xref ref-type="bibr" rid="R135">135</xref>-<xref ref-type="bibr" rid="R137">137</xref>, <xref ref-type="bibr" rid="R140">140</xref>, <xref ref-type="bibr" rid="R141">141</xref>, <xref ref-type="bibr" rid="R144">144</xref>-<xref ref-type="bibr" rid="R146">146</xref>]. However, it should be noted that the cardiac effects of somatostatin analogues seem to be related not only to the strict biochemical control of acromegaly, but also to the patient's age and the disease duration before starting treatment [<xref ref-type="bibr" rid="R22">22</xref>].</p></sec><sec><title>GH DEFICIENCY</title><p>Growth hormone deficiency produces different clinical features depending on the time of onset and disease severity and duration [<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R106">106</xref>, <xref ref-type="bibr" rid="R147">147</xref>]. GHD negatively affects cardiovascular function by directly acting on the heart and endothelium; it also acts indirectly by causing insulin resistance, abdominal obesity, hypercoagulability, increase in serum lipids, reduction in exercise performance and pulmonary capacity [<xref ref-type="bibr" rid="R148">148</xref>, <xref ref-type="bibr" rid="R149">149</xref>]. GHD patients have increased total body fat, atherothrombotic and proinflammatory abnormalities, dyslipidemia and decreased insulin-stimulated glucose uptake by fat and skeletal muscle [<xref ref-type="bibr" rid="R150">150</xref>, <xref ref-type="bibr" rid="R151">151</xref>]. In addition to the cardiovascular risk factors mentioned above, GHD patients have increased vessel intima-media thickness, which is the earliest morphological change in the development of atherosclerosis [<xref ref-type="bibr" rid="R149">149</xref>, <xref ref-type="bibr" rid="R152">152</xref>-<xref ref-type="bibr" rid="R155">155</xref>]. Patients with GHD are also affected by endothelial dysfunction, reduced NO production, high peripheral vascular resistance and enhanced aorta stiffness [<xref ref-type="bibr" rid="R152">152</xref>-<xref ref-type="bibr" rid="R157">157</xref>]. Furthermore, GHD affects cardiac size and function, thereby leading to a reduction in both myocardial growth rate and cardiac performance [<xref ref-type="bibr" rid="R158">158</xref>,<xref ref-type="bibr" rid="R159"> 159</xref>]. Cardiac function decreases because of reduced ventricular mass and intrinsic myocardial contractility [<xref ref-type="bibr" rid="R160">160</xref>].</p><p>Childhood-onset GHD is characterized by cardiac atrophy with a significant reduction in LV mass, relative wall thickness and cavity dimensions, compared with age-, sex- and height-matched controls [<xref ref-type="bibr" rid="R158">158</xref>-<xref ref-type="bibr" rid="R162">162</xref>]. Moreover, patients are affected by a hypokinetic syndrome, namely, they have a low ejection fraction, low cardiac output and high peripheral vascular resistance [<xref ref-type="bibr" rid="R158">158</xref>, <xref ref-type="bibr" rid="R160">160</xref>-<xref ref-type="bibr" rid="R163">163</xref>]. These alterations are more pronounced during physical exercise and, besides reducing skeletal muscle mass and strength, they reduce exercise capacity, as shown by subjective symptoms, low values of achieved workload and exercise duration [<xref ref-type="bibr" rid="R160">160</xref>,<xref ref-type="bibr" rid="R164"> 164</xref>-<xref ref-type="bibr" rid="R166">166</xref>]. Adult-onset GHD does not feature a reduction in cardiac mass, but only impaired cardiac performance and exercise capacity [<xref ref-type="bibr" rid="R165">165</xref>, <xref ref-type="bibr" rid="R167">167</xref>, <xref ref-type="bibr" rid="R168">168</xref>].</p><p>Evidence that cardiac alterations in GHD are strictly related to the GH deficiency comes from many GH replacement trials, which taken together show an increase in LV mass and improvement in cardiac performance, diastolic filling and systolic function after GH treatment [<xref ref-type="bibr" rid="R158">158</xref>-<xref ref-type="bibr" rid="R160">160</xref>, <xref ref-type="bibr" rid="R163">163</xref>, <xref ref-type="bibr" rid="R164">164</xref>, <xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R169">169</xref>-<xref ref-type="bibr" rid="R172">172</xref>]. Although some studies have failed to demonstrate an improvement in cardiac structure or function [<xref ref-type="bibr" rid="R173">173</xref>, <xref ref-type="bibr" rid="R174">174</xref>], a meta-analysis that included all trials on the effects of GH replacement included in Medline, Biosis and EMBASE from the year of their inception to June 2002, showed positive effects on LV mass, wall thickness, LV end-diastolic and end-systolic diameters and cardiac output [<xref ref-type="bibr" rid="R169">169</xref>]. All the GH replacement trials showed that cardiac function returns to the pre-treatment setting upon cessation of GH treatment [<xref ref-type="bibr" rid="R158">158</xref>-<xref ref-type="bibr" rid="R160">160</xref>, <xref ref-type="bibr" rid="R163">163</xref>, <xref ref-type="bibr" rid="R164">164</xref>, <xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R169">169</xref>-<xref ref-type="bibr" rid="R172">172</xref>, <xref ref-type="bibr" rid="R175">175</xref>].</p><p>The beneficial cardiovascular effects of GH replacement are related not only to cardiac anabolic actions but also to its peripheral effects. Treatment with GH normalizes NO production, thereby reducing peripheral vascular resistance and modulating cardiac cytoskeletal functions by altering calcium myofilament responsiveness [<xref ref-type="bibr" rid="R70">70</xref>, <xref ref-type="bibr" rid="R157">157</xref>]. Moreover, GH replacement improves body composition, which is an important factor for reducing cardiovascular risk [<xref ref-type="bibr" rid="R176">176</xref>, <xref ref-type="bibr" rid="R177">177</xref>], induces beneficial effects on lipid profile [<xref ref-type="bibr" rid="R178">178</xref>, <xref ref-type="bibr" rid="R179">179</xref>] and reduces arterial intima-media thickness [<xref ref-type="bibr" rid="R152">152</xref>, <xref ref-type="bibr" rid="R155">155</xref>, <xref ref-type="bibr" rid="R178">178</xref>, <xref ref-type="bibr" rid="R179">179</xref>].</p></sec><sec><title>GH AND HEART FAILURE</title><p>The rationale for GH therapy in CHF appears evident when considering the cardiovascular effects of GH and the cardiac morphological and functional features in heart failure. Patients with CHF have reduced myocardial contractility, decreased cardiac output, dilated LV cavity, increased peripheral vascular resistance and enhanced wall stress. Cardiac dilatation, which initially helps to maintain an adequate stroke volume, initiates a vicious cycle whereby dilatation leads to dilatation. GH replacement may be beneficial in all steps of heart failure. By stimulating cardiac growth, GH induces a concentric pattern of remodelling, which reduces wall stress. By decreasing peripheral vascular resistance, GH reduces afterload, attenuates pathologic cardiac remodelling and improves cardiac function. Furthermore, by inducing positive inotropic effects, GH directly counteracts the impaired contractility, which is the <italic>primum movens</italic> of the vicious cycle responsible for pathologic remodelling.</p><p>The pathogenesis and the progression of CHF seem to be related also to an imbalance between pro-inflammatory/anti-inflammatory factors and endothelial dysfunction. Patients with CHF have excessive plasma levels of pro-inflammatory cytokines and impaired vascular reactivity, which consists of attenuated vasodilatation in response to acetylcholine and preserved response to the direct NO donor nitroprusside. By shifting the cytokine balance toward anti-inflammatory predominance and reducing pro-apoptotic factors, GH positively acts on LV remodelling, increasing LV contractile performance and enhancing exercise capacity. In addition, GH is able to improve vascular reactivity, not only by restoring NO production, but also activating non-endothelium-mediated actions, in particular by modifying intracellular calcium concentration and regulating Na<sup>+</sup>/K<sup>+</sup> ATPase activity.</p></sec><sec><title>EXPERIMENTAL STUDIES ON ANIMALS</title><p>The first study of the effects of the GH/IGF-1 system in experimental heart failure models dates back to 1992. At that time, Castagnino and colleagues evaluated the effect of GH on the connective tissue, fibroblast growth and proliferation in rats with experimental myocardial infarction, and found a significant decrease in the incidence of ventricular aneurysms [<xref ref-type="bibr" rid="R180">180</xref>]. A subsequent study, designed to assess the effects of IGF-1 on cardiac function and structure in rats with a doxorubicin-induced cardiomyopathy, showed that IGF-1 increases cardiac output as well as reduces histologically-detected myocyte damage [<xref ref-type="bibr" rid="R181">181</xref>]. In this scenario, Ito and co-workers proved, in cultured neonatal cardiomyocytes, that IGF-1, but not GH, promotes transcription of muscle-specific genes (namely, troponin I, myosin light chain-2, and &#x003b1;-actin), induces protein synthesis and increases myocyte size [<xref ref-type="bibr" rid="R75">75</xref>]. Duerr and colleagues demonstrated that IGF-1, administrated in rats early during the onset of experimental post-infarction heart failure, enhances the hypertrophic response of viable myocardium and cardiac performance [<xref ref-type="bibr" rid="R182">182</xref>]. Similarly, Cittadini and co-workers, investigating the cardiac effects of GH adminis-tration during the early phase of pathologic remodelling in a rat model of large myocardial infarction, confirmed that GH causes hypertrophy of the non-infarcted myocardium in a concentric pattern and improves LV function [<xref ref-type="bibr" rid="R183">183</xref>]. Two subsequent trials showed that GH plus IGF-1, given to rats with LV failure, starting one month after myocardial infarction, and then in the late phase of LV remodelling, improved cardiac function and reduced peripheral vascular resistance and LV dilatation [<xref ref-type="bibr" rid="R184">184</xref>, <xref ref-type="bibr" rid="R185">185</xref>]. Other experimental studies confirmed that GH attenuates both the early and the late pathologic LV remodelling, induces hypertrophy of non-infarcted myocardium, improves LV function and increases cardiac output [<xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R187">187</xref>].</p><p>Cittadini and co-workers administered GH or IGF-1 or GH plus IGF-1 to adult HF rats and found a significant increase in cardiac performance and LV mass, without development of significant fibrosis, and no additional hypertrophy in rats receiving GH plus IGF-1 compared with rats treated singularly with GH or IGF-1 alone. This interesting result suggested that, <italic>in vivo</italic>, IGF-1 mediates the GH-induced cardiac hypertrophy [<xref ref-type="bibr" rid="R188">188</xref>]. Subsequent studies confirmed that GH/IGF-1 modifies cardiac structure, reduces interstitial fibrosis and improves myocardial function [<xref ref-type="bibr" rid="R189">189</xref>-<xref ref-type="bibr" rid="R191">191</xref>].</p><p>More recently, Cittadini and colleagues demonstrated, in a rat model of post-infarction heart failure, that GH improves a broad spectrum of structural abnormalities of the extra-cellular matrix [<xref ref-type="bibr" rid="R187">187</xref>]. Specifically, they found a decrease in the collagen volume fraction and in the collagen I/III ratio, and an increase in capillary density. The authors hypothesized that GH attenuates fibrosis, directly by reducing collagen synthesis or increasing its breakdown, and indirectly by reducing accumulation of extracellular matrix proteins in the interstitial space. This latter was explained as due to the GH-induced improvement in hemodynamic and to the decrease in wall stress [<xref ref-type="bibr" rid="R187">187</xref>]. Cittadini and colleagues supposed that GH reduces interstitial fibrosis thanks also to its anti-apoptotic properties. Although apoptosis <italic>per se</italic> does not induce fibrosis, it leaves myocardial defects that are filled with interstitial fluid from myocardial edema, subsequently leading to fibrous tissue accumulation [<xref ref-type="bibr" rid="R187">187</xref>]. GH and IGF-1 exert direct beneficial effects on myocyte contractile performance in heart failure models, not solely by stimulating cardiac growth, modifying cardiac structure, reducing interstitial fibrosis or inducing peripheral vasodilatation, but also by changing calcium handling and the inotropic state [<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R88">88</xref>, <xref ref-type="bibr" rid="R192">192</xref>-<xref ref-type="bibr" rid="R195">195</xref>]. Kinugawa and colleagues demonstrated that acute IGF-1 administration in isolated cardiomyocytes, in both normal and heart failure conditions, exerts a direct positive inotropic effect, due to calcium transient amplitude and calcium availability to the contractile apparatus [<xref ref-type="bibr" rid="R193">193</xref>]. They also showed IGF-1 does not modify the terminal portion of the relaxation phase trajectory, which indicates that calcium sensitivity is not altered by IGF-1 administration [<xref ref-type="bibr" rid="R193">193</xref>]. This result was consistent with previous studies in which acute IGF-1 administration increases the contractility of cardiomyocytes and isolated ventricular muscle [<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R88">88</xref>]. In addition, Freestone and colleagues reported that, in isolated rat cardiac muscle, acute IGF-1 administration had a positive inotropic effect, in fact, it increased the peak of cytosolic free calcium concentration, the amplitude of calcium transient and the time to peak [<xref ref-type="bibr" rid="R194">194</xref>]. In contrast with these results, Cittadini and co-workers showed that, in isolated isovolumic aequorin-loaded rat whole hearts and ferret papillary muscles, IGF-1 administration produces an acute positive inotropic effect, not associated with an increased intra-cellular calcium availability but to a significant increase of myofilament calcium sensitivity [<xref ref-type="bibr" rid="R82">82</xref>]. All these experimental studies, in which GH did not induce acute effects on cardiac function, and IGF-1 positively affected cardiac contractility, provide further insight into the intricate interaction between the GH/IGF-1 axis and cardiovascular system. In fact, although GHRs are expressed on the heart, their physio-logical role probably does not include acute modulation of myocardial contractility, but they serve to mediate such other functions as protein synthesis or local IGF-1 production [<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R88">88</xref>, <xref ref-type="bibr" rid="R193">193</xref>, <xref ref-type="bibr" rid="R194">194</xref>].</p><p>Von Lewinski and colleagues were the first to study the functional effects of IGF-1 in isolated human myocardium. They demonstrated that IGF-1: 1) exerts a concentration-dependent positive inotropic effect, which is almost completely prevented by blocking its receptors or phosphoinositide 3-kinase (PI3-kinase); 2) increases L-type calcium currents; 3) activates Na<sup>+</sup>-H<sup>+</sup> and reversed Na<sup>+</sup>-Ca<sup>2+</sup> exchanges [<xref ref-type="bibr" rid="R196">196</xref>]. The beneficial effects of GH treatment in heart failure may be also related to the anti-apoptotic proprieties of the GH/IGF-1 system [<xref ref-type="bibr" rid="R80">80</xref>, <xref ref-type="bibr" rid="R81">81</xref>, <xref ref-type="bibr" rid="R187">187</xref>, <xref ref-type="bibr" rid="R197">197</xref>]. Although cardiomyocytes were long thought not undergo apoptosis, it is now recognized that cardiomyocyte apoptosis is increased in CHF and it may play a key role in CHF progression. Cardiomyocyte apoptosis occurs in the early stages of myocardial dysfunction; it impairs LV performance by reducing the contractile mass of the heart and by contributing to the progressive loss of myocytes [<xref ref-type="bibr" rid="R198">198</xref>, <xref ref-type="bibr" rid="R199">199</xref>]. The anti-apoptotic effects of GH do not appear to be mediated by IGF-1: Gonzalez-Juanatey and co-workers demonstrated, in primary cultures of rat neonatal cardiomyocytes, that GH regulates apoptosis through the inhibition of calcineurin, a calcium-dependent phosphatase [<xref ref-type="bibr" rid="R197">197</xref>]. Others showed that the effects exerted by GH on cell survival and proliferation are mediated through two different signalling pathways, involving nuclear factor-kappa B (NF-kB) and PI3-kinase, respectively, which promote high circulating levels of the anti-apoptotic molecules [<xref ref-type="bibr" rid="R200">200</xref>-<xref ref-type="bibr" rid="R202">202</xref>].</p></sec><sec><title>CLINICAL STUDIES IN HUMANS WITH HEART FAILURE</title><p>Several research groups have studied the effects of GH and IGF-1 in patients with impaired cardiac function (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). The first results were limited to case reports showing that GH administration considerably improved cardiac function [<xref ref-type="bibr" rid="R203">203</xref>, <xref ref-type="bibr" rid="R204">204</xref>]. The earliest open clinical trial in CHF was reported by Fazio and co-workers in 1996 [<xref ref-type="bibr" rid="R90">90</xref>]. They studied seven patients with idiopathic dilated cardiomyopathy, with moderate to severe heart failure, without GHD. The evaluation was performed at baseline, after three months of recombinant  human  GH  (rhGH)  therapy  and three months after therapy discontinuation. They assessed cardiac function with Doppler echocardiography, right-heart catheterization and exercise testing. After three months of treatment at a dose of 4 international units every other day, they found improvement in cardiac performance, exercise tolerance, hemodynamic profile and myocardial energetic metabolism. Transthoracic echocardiography revealed a significant increase in relative wall thickness and cardiac mass, a dramatic decrease in wall stress and an improvement in systolic performance indices (ejection fraction, shortening velocity and aortic acceleration). Using right-heart catheterization to evaluate the effects of rhGH on hemodynamic variables, at rest and in response to physical exercise, they found significant decrease in mean pulmonary arterial and capillary wedge pressures, increased cardiac output and reduced systemic vascular resistance. The also demonstrated beneficial changes in myocardial energetic metabolism, particularly during physical exercise, i.e., the heart generated more mechanical work with lower oxygen consumption and energy production. This improvement in energetic metabolism was attributed to wall stress reduction and not to change in metabolic substrates. These encouraging preliminary findings prompted several larger and controlled clinical trials.</p><p>Conflicting results emerged from a randomized, double-blind, placebo-controlled rhGH treatment study, which showed, in fifty CHF patients, an increase in LV mass related to serum IGF-1 level but no change in LV wall stress, arterial blood pressure, ejection fraction, clinical status or 6-minute walking distance [<xref ref-type="bibr" rid="R205">205</xref>]. Similarly, in another clinical trial, carried out in twenty-two patients with CHF of various etiologies, rhGH treatment did not significantly affect clinical status, exercise duration, ejection fraction, end-diastolic and end-systolic volumes. Furthermore, no significant increases in LV mass and wall thickness were shown [<xref ref-type="bibr" rid="R206">206</xref>]. On the contrary, rhGH significantly increased exercise capacity and decreased LV end-systolic and end-diastolic volumes in patients with post-ischemic CHF [<xref ref-type="bibr" rid="R207">207</xref>]. The patients also had a 15% increase in posterior wall thickness and 16% increase in cardiac output [<xref ref-type="bibr" rid="R207">207</xref>]. rhGH did not affect cardiac structure but greatly improved exercise performance and quality of life in ten post-ischemic CHF patients [<xref ref-type="bibr" rid="R208">208</xref>]. Conflicting results were obtained from other numerous experimental trials. For instance, some studies showed that rhGH caused a significant increase in cardiac performance [<xref ref-type="bibr" rid="R209">209</xref>-<xref ref-type="bibr" rid="R211">211</xref>], whereas others found no changes [<xref ref-type="bibr" rid="R212">212</xref>-<xref ref-type="bibr" rid="R214">214</xref>].</p><p>More recently, Adamopoulos and colleagues investigated the immunomodulatory role of rhGH administration in CHF patients. They found that a three-month course of GH normalizes circulating levels of proinflammatory cytokines, such as tumour necrosis factor &#x003b1; (TNF-&#x003b1;) and interleukin- 6 (IL-6), their soluble receptors, as well as apoptosis mediators, such as soluble Fas (sFas) and soluble Fas ligand (sFasL) [<xref ref-type="bibr" rid="R215">215</xref>, <xref ref-type="bibr" rid="R216">216</xref>]. They subsequently reported that GH reduces the soluble adhesion molecules ICAM-1 and VCAM-1, the granulocyte-macrophage colony-stimulating factor (GM-CSF), which generates free radicals and enhances cytokine production, and the macrophage chemoattractant protein-1 (MCP-1), which promotes the migration of mononuclear phagocytes into the injured myocardial tissue and endothelial cells [<xref ref-type="bibr" rid="R217">217</xref>]. To evaluate whether these changes are related to modifications in exercise tolerance and echocardiographic markers of cardiac remodelling and performance, they found a significantly correlation between improvement in exercise capacity and restoration to the normal of the inflammatory response, as well as a good correlation between exercise capacity improvement and reduction in adhesion molecules and in soluble apoptosis mediators. They also showed that GH induced a decrease in end systolic wall stress and an increase in contractile reserve and that these changes were correlated with the decrease in the chemotactic protein MCP-1 and pro-inflammatory cytokines [<xref ref-type="bibr" rid="R215">215</xref>-<xref ref-type="bibr" rid="R217">217</xref>].</p><p>In an attempt to gain further insight into the mechanisms by which GH may benefit CHF patients, Fazio and co-workers have recently carried out a double-blind, placebo-controlled study of the effects of GH on physical exercise capacity and cardiopulmonary performance in twenty-two patients with moderate heart failure [<xref ref-type="bibr" rid="R218">218</xref>]. Patients underwent spirometry, cardiopulmonary exercise testing and Doppler echocardiography. The baseline clinical status was comparable in the GH patients and in the placebo group. After three months of treatment, at exercise testing, the GH group had an improvement of exercise capacity, cardio-pulmonary performance, and ventilatory efficiency, with a significant increase of VO2max and of chronotropic index (Fig. <bold><xref ref-type="fig" rid="F2">2</xref></bold>).</p><p>Moreover, at transthoracic echocardiography, the GH group had an increase in LV mass index, relative wall thickness and cardiac performance. The LV ejection fraction and early-to-late mitral peak velocity ratio were significantly.</p><p>The conflicting results of the clinical trials of GH treatment analyzed in this review may be related to the small number of patients enrolled, the different dose and duration of GH treatment, the different CHF etiologies, and differences in the patients' demographic, hemodymamic and clinical characteristics. This discrepancy may also reflect the heterogeneity of IGF-1 increase in response to GH. In fact, a recent meta-analysis, which analyzed all randomized controlled trials and open studies on sustained GH treatment in adults with CHF in the absence of GHD, contained in the Medline, Biosis and EMBASE databases from their inception to June 2005, confirms that there is a close relationship between change in IGF-1 concentration and GH effects [<xref ref-type="bibr" rid="R219">219</xref>]. When the studies were divided into two groups based on the degree of IGF-1 increment, in trials with an IGF-1 increase &#x0003e;89% versus baseline there was a significant improvement in cardiac performance, echocardiographic parameters and exercise capacity, whereas in trials with an IGF-1 increase &#x0003c;89% there were no beneficial cardiovascular effects. In other words, patients with a blunted IGF-1 response to exogenous GH administration are less likely to benefit from GH treatment. This suggests that some patients may be not &#x0201c;sensitive&#x0201d; to GH. Therefore, &#x0201c;responders&#x0201d; should be identified before starting GH treatment in CHF patients.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Although experimental models and preliminary human studies have demonstrated that GH administration may have beneficial cardiovascular effects in CHF, more experimental and clinical studies are necessary to clarify the mechanisms that determine the variable sensitivity to GH and its positive effects in the failing heart.</p></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>We are grateful to Jean Ann Gilder for text editing.</p></ack><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duello</surname><given-names>TM</given-names></name><name><surname>Halmi</surname><given-names>NS</given-names></name></person-group><article-title>Ultrastructural-immunocytochemical localization of growth hormone and prolactin in human pituitaries</article-title><source>J Clin Endocrinol Metab</source><year>1979</year><volume>49</volume><fpage>189</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">379029</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thorner</surname><given-names>MO</given-names></name><name><surname>Vance</surname><given-names>ML</given-names></name><name><surname>Horvath</surname><given-names>E</given-names></name><name><surname>Kovacs</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wilson</surname><given-names>JD</given-names></name><name><surname>Foster</surname><given-names>DW</given-names></name></person-group><source>Textbook of Endocrinology. The anterior pituitary</source><year>1992</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>WB Saunders Co</publisher-name><fpage>221</fpage><lpage>310</lpage></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannenbaum</surname><given-names>GS</given-names></name><name><surname>Ling</surname><given-names>N</given-names></name></person-group><article-title>The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion</article-title><source>Endocrinology</source><year>1984</year><volume>115</volume><fpage>1952</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">6149116</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotsky</surname><given-names>PM</given-names></name><name><surname>Vale</surname><given-names>W</given-names></name></person-group><article-title>Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophyseal-portal circulation of the rat</article-title><source>Science</source><year>1985</year><volume>230</volume><fpage>461</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">2864742</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arce</surname><given-names>V</given-names></name><name><surname>Lima</surname><given-names>L</given-names></name><name><surname>Lois</surname><given-names>N</given-names></name><etal/></person-group><article-title>Role of central dopaminergic pathways in the neural control of growth hormone secretion in normal men: studies with metoclopramide</article-title><source>Neuroendocrinology</source><year>1991</year><volume>53</volume><fpage>143</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1673022</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillemin</surname><given-names>R</given-names></name><name><surname>Brazeau</surname><given-names>P</given-names></name><name><surname>Bohlen</surname><given-names>P</given-names></name><name><surname>Esch</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>N</given-names></name><name><surname>Wehrenberg</surname><given-names>WB</given-names></name></person-group><article-title>Growth hormone releasing factor from a human pancreatic tumor that caused acromegaly</article-title><source>Science</source><year>1982</year><volume>218</volume><fpage>585</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6812220</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazeau</surname><given-names>P</given-names></name><name><surname>Vale</surname><given-names>W</given-names></name><name><surname>Burgus</surname><given-names>R</given-names></name><etal/></person-group><article-title>Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone</article-title><source>Science</source><year>1973</year><volume>179</volume><fpage>77</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">4682131</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanueva</surname><given-names>FF</given-names></name></person-group><article-title>Physiology of growth hormone secretion and action</article-title><source>Endocrinol Metab Clin North Am</source><year>1992</year><volume>21</volume><fpage>483</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">1521508</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laron</surname><given-names>Z</given-names></name></person-group><article-title>Growth hormone secretagogues: clinical, experimental and therapeutic potential</article-title><source>Drugs</source><year>1995</year><volume>50</volume><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">8536548</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomberg-Maitland</surname><given-names>M</given-names></name><name><surname>Frishman</surname><given-names>WH</given-names></name></person-group><article-title>Recombinant growth hormone: a new cardiovascular drug therapy</article-title><source>Am Heart J</source><year>1996</year><volume>132</volume><fpage>1244</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">8969577</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobl</surname><given-names>JS</given-names></name><name><surname>Thomas</surname><given-names>MJ</given-names></name></person-group><article-title>Human growth hormone</article-title><source>Pharmacol Rev</source><year>1995</year><volume>46</volume><fpage>1</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">8190748</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapanaienen</surname><given-names>P</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of growth hormone secretion and treatment</article-title><source>Ann Med</source><year>1992</year><volume>24</volume><fpage>237</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">1389086</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dronby</surname><given-names>EC</given-names></name><name><surname>Amburn</surname><given-names>K</given-names></name><name><surname>Powmakn</surname><given-names>G</given-names></name></person-group><article-title>Circadian variation of basal growth hormone in man</article-title><source>J Clin Endocrin Metab</source><year>1983</year><volume>57</volume><fpage>524</fpage><lpage>8</lpage></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Jorgensen</surname><given-names>JOL</given-names></name><name><surname>Abildgard</surname><given-names>N</given-names></name><name><surname>Orskov</surname><given-names>L</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name></person-group><article-title>Effects of growth hormone on glucose metabolism</article-title><source>Horm Res</source><year>1991</year><volume>36</volume><fpage>32</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1806481</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betherat</surname><given-names>J</given-names></name><name><surname>Bluet-Pajt</surname><given-names>MT</given-names></name><name><surname>Eppelbaun</surname><given-names>J</given-names></name></person-group><article-title>Neuroendocrine regulation of growth hormone</article-title><source>Eur J Endocrinol</source><year>1995</year><volume>132</volume><fpage>12</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7850005</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudman</surname><given-names>D</given-names></name><name><surname>Kutner</surname><given-names>MH</given-names></name><name><surname>Rogers</surname><given-names>MC</given-names></name><name><surname>Lubin</surname><given-names>MF</given-names></name><name><surname>Fleming</surname><given-names>Ga</given-names></name><name><surname>Bain</surname><given-names>RP</given-names></name></person-group><article-title>Impaired growth hormone secretion in the adult population. Relation to age and adiposity</article-title><source>J Clin Invest</source><year>1981</year><volume>67</volume><fpage>1361</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7194884</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudman</surname><given-names>D</given-names></name></person-group><article-title>Growth hormone, body composition and aging</article-title><source>J Am Geriatr Soc</source><year>1985</year><volume>33</volume><fpage>800</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3902942</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>BT</given-names></name></person-group><article-title>Growth hormone and the somatomedins: a historical perspective and current concepts</article-title><source>Ann Clin Biochem</source><year>1991</year><volume>28</volume><fpage>542</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">1776804</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathews</surname><given-names>LS</given-names></name><name><surname>Enberg</surname><given-names>B</given-names></name><name><surname>Norstedt</surname><given-names>G</given-names></name></person-group><article-title>Regulation of rat growth hormone receptor gene expression</article-title><source>J Biol Chem</source><year>1989</year><volume>17</volume><fpage>9905</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">2722883</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiropoulos</surname><given-names>A</given-names></name><name><surname>Perrot-Applanat</surname><given-names>M</given-names></name><name><surname>Dinerstein</surname><given-names>H</given-names></name><etal/></person-group><article-title>Distinct cytoplasmatic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription</article-title><source>Endocrinology</source><year>1994</year><volume>135</volume><fpage>1289</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7925091</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>LE</given-names></name><name><surname>Van Wyk</surname><given-names>JJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wilson</surname><given-names>JD</given-names></name><name><surname>Foster</surname><given-names>DW</given-names></name></person-group><source>Textbook of Endocrinology. Normal and aberrant growth</source><year>1992</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>WB Saunders Co</publisher-name><fpage>1079</fpage><lpage>138</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Vitale</surname><given-names>G</given-names></name><name><surname>Pivonello</surname><given-names>R</given-names></name><name><surname>Ciccarelli</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name></person-group><article-title>The heart: an end-organ of GH action</article-title><source>Eur J Endocrinol</source><year>2004</year><volume>151</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">15248827</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froesch</surname><given-names>ER</given-names></name><name><surname>Schnid</surname><given-names>C</given-names></name><name><surname>Schwander</surname><given-names>J</given-names></name><name><surname>Zapf</surname><given-names>J</given-names></name></person-group><article-title>Action of insulin-like growth factors</article-title><source>Annu Rev Physiol</source><year>1985</year><volume>47</volume><fpage>443</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">2986538</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaksson</surname><given-names>OG</given-names></name><name><surname>Lindahl</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Isgaard</surname><given-names>J</given-names></name></person-group><article-title>Action of growth hormone: current views</article-title><source>Acta Paediatr Scand</source><year>1988</year><volume>343</volume><fpage>12</fpage><lpage>8</lpage></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laron</surname><given-names>Z</given-names></name></person-group><article-title>Somatomedin, insulin, growth hormone and growth: a review</article-title><source>Isr J Med Sci</source><year>1982</year><volume>18</volume><fpage>823</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6749757</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>WD</given-names></name><name><surname>Daughaday</surname><given-names>H</given-names></name></person-group><article-title>A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage <italic>in vitro</italic></article-title><source>J Lab Clin Med</source><year>1957</year><volume>49</volume><fpage>825</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">13429201</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daughaday</surname><given-names>WH</given-names></name><name><surname>Karl</surname><given-names>IE</given-names></name><name><surname>Karl</surname><given-names>MM</given-names></name></person-group><article-title>A failed assay opened a new door in growth hormone research</article-title><source>Endocrinology</source><year>1992</year><volume>130</volume><fpage>565</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1733709</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>LJ</given-names></name><name><surname>Bell</surname><given-names>GI</given-names></name><name><surname>Friesen</surname><given-names>Hg</given-names></name></person-group><article-title>Growth hormone stimulates sequential induction of c-myc and insulin-like growth factor I expression <italic>in vivo</italic></article-title><source>Endocrinology</source><year>1987</year><volume>120</volume><fpage>1806</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">3569112</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>RD</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Ren</surname><given-names>SG</given-names></name><name><surname>Chelly</surname><given-names>M</given-names></name><name><surname>Umehara</surname><given-names>Y</given-names></name><name><surname>Melmed</surname><given-names>S</given-names></name></person-group><article-title>Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>349</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15286801</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacc&#x000e0;</surname><given-names>L</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Fazio</surname><given-names>S</given-names></name></person-group><article-title>Growth hormone and the heart</article-title><source>Endocr Rev</source><year>1994</year><volume>15</volume><fpage>555</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">7843068</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Palmieri</surname><given-names>EA</given-names></name><name><surname>Biondi</surname><given-names>B</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Sacc&#x000e0;</surname><given-names>L</given-names></name></person-group><article-title>The role of the GH-IGF-1 axis in the regulation of myocardial growth: from experimental model to human evidence</article-title><source>Eur J Endocrinol</source><year>2000</year><volume>142</volume><fpage>211</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10700713</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>DE</given-names></name><name><surname>Cuneo</surname><given-names>RC</given-names></name></person-group><article-title>Controversies regarding the effects of growth hormone on the heart</article-title><source>Mayo Clin Proc</source><year>2003</year><volume>78</volume><fpage>1521</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14661681</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>J</given-names></name><name><surname>Tivesten</surname><given-names>A</given-names></name><name><surname>Isgaard</surname><given-names>J</given-names></name></person-group><article-title>Growth hormone and the cardiovascular function</article-title><source>Minerva Endocrinol</source><year>2005</year><volume>30</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15877009</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foncea</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Ketterman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>19115</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">9235900</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>R</given-names></name><name><surname>Bonelli</surname><given-names>L</given-names></name><name><surname>Marinazzo</surname><given-names>E</given-names></name><name><surname>Ghigo</surname><given-names>E</given-names></name><name><surname>Arvat</surname><given-names>E</given-names></name></person-group><article-title>Growth hormone treatment in human aging: benefit and risks</article-title><source>Hormones</source><year>2008</year><volume>7</volume><issue>2</issue><fpage>133</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18477550</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Meites</surname><given-names>J</given-names></name></person-group><article-title>GH binding to liver in young and old female rats: relation to somatomedin-C secretion</article-title><source>Proc Soc Exp Biol Med</source><year>1987</year><volume>186</volume><fpage>229</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">3671361</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Bennett</surname><given-names>SA</given-names></name><name><surname>Ingram</surname><given-names>RL</given-names></name><name><surname>Sonntag</surname><given-names>WE</given-names></name></person-group><article-title>Decreases in growth hormone receptor signal transduction contribute to the decline in insulin-like growth factor I gene expression with age</article-title><source>Endocrinology</source><year>1995</year><volume>136</volume><fpage>4551</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7664676</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Costa</surname><given-names>AP</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Ingram</surname><given-names>RL</given-names></name><name><surname>Sonntag</surname><given-names>WE</given-names></name></person-group><article-title>Insulin-like growth factor-1 stimulation of protein synthesis is attenuated in cerebral cortex of aging rats</article-title><source>Neuroscience</source><year>1995</year><volume>65</volume><fpage>805</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">7609879</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>CR</given-names></name><name><surname>Brenelli</surname><given-names>SL</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidy-linositol 3-kinase in liver and muscle of rats</article-title><source>Endocrinology</source><year>1996</year><volume>137</volume><fpage>51</fpage><lpage>9</lpage></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Sonntag</surname><given-names>WE</given-names></name></person-group><article-title>Growth hormone-induced nuclear translocation of Stat-3 decreases with age: modulation by caloric restriction</article-title><source>Am J Physiol</source><year>1996</year><volume>271</volume><fpage>E903</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8944679</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roupas</surname><given-names>P</given-names></name><name><surname>Herington</surname><given-names>AC</given-names></name></person-group><article-title>Postreceptor signaling mechanisms for growth hormone</article-title><source>Trends Endocrinol Metab</source><year>1994</year><volume>5</volume><fpage>154</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18407202</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitahara</surname><given-names>JA</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intracellular calcium, DNase activity and myocyte apoptosis in aging Fischer 344 rats</article-title><source>J Mol Cell Cardiol</source><year>1998</year><volume>30</volume><fpage>519</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">9515029</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivetti</surname><given-names>G</given-names></name><name><surname>Melissari</surname><given-names>M</given-names></name><name><surname>Capasso</surname><given-names>JM</given-names></name><name><surname>Anversa</surname><given-names>P</given-names></name></person-group><article-title>Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy</article-title><source>Circ Res</source><year>1991</year><volume>68</volume><fpage>1560</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2036710</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corpas</surname><given-names>E</given-names></name><name><surname>Harman</surname><given-names>SM</given-names></name><name><surname>Blackman</surname><given-names>MR</given-names></name></person-group><article-title>Human growth hormone and human aging</article-title><source>Endocr Rev</source><year>1993</year><volume>14</volume><fpage>20</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">8491152</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eghbali</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>TF</given-names></name><name><surname>Seifter</surname><given-names>S</given-names></name><name><surname>Blumenfeld</surname><given-names>OO</given-names></name></person-group><article-title>Collagen accumulation in heart ventricles as a function of growth and aging</article-title><source>Cardiovasc Res</source><year>1989</year><volume>23</volume><fpage>723</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2598224</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudman</surname><given-names>D</given-names></name><name><surname>Kutner</surname><given-names>MH</given-names></name><name><surname>Rogers</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Impaired growth hormone secretion in the adult population: relation to age and adiposity</article-title><source>J Clin Invest</source><year>1981</year><volume>67</volume><fpage>1361</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7194884</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghigo</surname><given-names>E</given-names></name><name><surname>Goffi</surname><given-names>S</given-names></name><name><surname>Nicolosi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man</article-title><source>J Clin Endocrinol Metab</source><year>1990</year><volume>71</volume><fpage>1481</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2229304</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bichell</surname><given-names>DP</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Rotwein</surname><given-names>P</given-names></name></person-group><article-title>Growth hormone rapidly activates insulin-like growth factor I gene transcription <italic>in vivo</italic></article-title><source>Mol Endocrinol</source><year>1992</year><volume>6</volume><fpage>1899</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">1480177</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrado</surname><given-names>J</given-names></name><name><surname>Bougria</surname><given-names>M</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Castano</surname><given-names>A</given-names></name><name><surname>Machado</surname><given-names>A</given-names></name></person-group><article-title>Effects of aging on the various steps of protein synthesis: fragmentation of elongation factor 2</article-title><source>Free Radic Biol Med</source><year>1999</year><volume>26</volume><fpage>362</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9895228</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxley</surname><given-names>HE</given-names></name></person-group><article-title>The crossbridge mechanism of muscular contraction and its implications</article-title><source>J Exp Biol</source><year>1985</year><volume>115</volume><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">3897443</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouillon</surname><given-names>R</given-names></name></person-group><article-title>Growth hormone and bone</article-title><source>Horm Res</source><year>1991</year><volume>36</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">1806485</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MB</given-names></name></person-group><article-title>Effects of growth hormone on carbohydrate and lipid metabolism</article-title><source>Endocri Rev</source><year>1987</year><volume>8</volume><fpage>115</fpage><lpage>31</lpage></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>U</given-names></name><name><surname>Miles</surname><given-names>JM</given-names></name></person-group><article-title>Growth hormone and lipids</article-title><source>Horm Res</source><year>1991</year><volume>36</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">1806482</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hjalmarson</surname><given-names>A</given-names></name><name><surname>Isaksson</surname><given-names>O</given-names></name><name><surname>Ahren</surname><given-names>K</given-names></name></person-group><article-title>Effects of growth hormone and insulin on amino acid transport in perfused heart rat</article-title><source>Am J Physiol</source><year>1969</year><volume>217</volume><fpage>1795</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">5353056</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saloman</surname><given-names>F</given-names></name><name><surname>Cuneo</surname><given-names>R</given-names></name><name><surname>Sonksen</surname><given-names>PH</given-names></name></person-group><article-title>Growth hormone and protein metabolism</article-title><source>Horm Res</source><year>1991</year><volume>36</volume><fpage>41</fpage><lpage>3</lpage></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czernichow</surname><given-names>P</given-names></name></person-group><article-title>Growth hormone administration and carbohydrate metabolism</article-title><source>Horm Res</source><year>1993</year><volume>39</volume><fpage>102</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8262468</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunfeld</surname><given-names>C</given-names></name><name><surname>Sherman</surname><given-names>BM</given-names></name><name><surname>Cavalieri</surname><given-names>RR</given-names></name></person-group><article-title>The acute effects of human growth hormone administration on thyroid function in normal man</article-title><source>J Clin Endocrinol Metab</source><year>1988</year><volume>67</volume><fpage>1111</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">3182961</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>KY</given-names></name><name><surname>Kelly</surname><given-names>JJ</given-names></name></person-group><article-title>Role of growth hormone in fluid homeostasis</article-title><source>Horm Res</source><year>1991</year><volume>36</volume><fpage>44</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1806484</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>J</given-names></name><name><surname>Jorgensen</surname><given-names>JOL</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Hansen</surname><given-names>KW</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name></person-group><article-title>Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man</article-title><source>J Clin Endocrinol Metab</source><year>1991</year><volume>72</volume><fpage>768</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">1826008</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MF</given-names></name><name><surname>Barazi</surname><given-names>M</given-names></name><name><surname>Pete</surname><given-names>G</given-names></name><name><surname>Muniyappa</surname><given-names>R</given-names></name><name><surname>Dunbar</surname><given-names>JC</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>Insulin-like growth factor I diminishes <italic>in vivo</italic> and <italic>in vitro</italic> vascular contractility: role of vascular nitric oxide</article-title><source>Endocrinology</source><year>1996</year><volume>137</volume><fpage>1798</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">8612517</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>H</given-names></name><name><surname>Gordienko</surname><given-names>DV</given-names></name><name><surname>Tonshoff</surname><given-names>B</given-names></name><name><surname>Gelato</surname><given-names>MC</given-names></name><name><surname>Goligorsky</surname><given-names>MS</given-names></name></person-group><article-title>Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells</article-title><source>Kidney Int</source><year>1994</year><volume>45</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">7513035</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muniyappa</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>MF</given-names></name><name><surname>Rangi</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production</article-title><source>Life Sci</source><year>1997</year><volume>61</volume><fpage>925</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9284085</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haylor</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Nahas</surname><given-names>AM</given-names></name></person-group><article-title>Nitric oxide synthesis inhibitor prevents vasodilatation by insulin-like growth factor I</article-title><source>Kidney Int</source><year>1991</year><volume>39</volume><fpage>333</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2002647</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasdai</surname><given-names>D</given-names></name><name><surname>Rizza</surname><given-names>RA</given-names></name><name><surname>Holmes DR</surname><given-names>Jr</given-names></name><name><surname>Richardson</surname><given-names>DM</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group><article-title>Insulin and insulin-like growth factor-I cause coronary vasorelaxation <italic>in vitro</italic></article-title><source>Hypertension</source><year>1998</year><volume>32</volume><fpage>228</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9719047</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caidahl</surname><given-names>K</given-names></name><name><surname>Eden</surname><given-names>S</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name></person-group><article-title>Cardiovascular and renal effects of growth hormone</article-title><source>Clin Endocrinol (Oxf)</source><year>1994</year><volume>40</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">8187304</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fryburg</surname><given-names>D</given-names></name></person-group><article-title>N<sup>G</sup>- monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF-1. Possible role of nitric oxide in muscle protein synthesis</article-title><source>J Clin Invest</source><year>1996</year><volume>97</volume><fpage>1319</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">8636445</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capaldo</surname><given-names>B</given-names></name><name><surname>Guardasole</surname><given-names>V</given-names></name><name><surname>Pardo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Abnormal vascular reactivity in growth hormone deficiency</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>520</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11157716</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>R</given-names></name><name><surname>Guardasole</surname><given-names>V</given-names></name><name><surname>Matarazzo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Growth hormone corrects vascular dysfunction in patients with chronic heart failure</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><fpage>90</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11755292</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joannides</surname><given-names>R</given-names></name><name><surname>Haefeli</surname><given-names>WE</given-names></name><name><surname>Linder</surname><given-names>L</given-names></name><etal/></person-group><article-title>Nitric oxide is responsible for flow-dependent dilation of peripheral conduit arterias <italic>in vivo</italic></article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>1314</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7867167</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badorff</surname><given-names>C</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name></person-group><article-title>NO balance: regulation of the cytoskeleton in congestive heart failure by nitric oxide</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>1348</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12642351</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Standley</surname><given-names>PR</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zayas</surname><given-names>RM</given-names></name><etal/></person-group><article-title>IGF-1 regulation of Na(+)-K(+)-ATPase in rat arterial smooth muscle</article-title><source>Am J Physiol</source><year>1997</year><volume>273</volume><fpage>113</fpage><lpage>21</lpage></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tivesten</surname><given-names>A</given-names></name><name><surname>Barlind</surname><given-names>A</given-names></name><name><surname>Caidahl</surname><given-names>K</given-names></name><etal/></person-group><article-title>Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the vascular smooth muscle KATP channel</article-title><source>J Endocrinol</source><year>2004</year><volume>183</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15525587</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>A</given-names></name><name><surname>Kurachi</surname><given-names>A</given-names></name><name><surname>Kurachi</surname><given-names>Y</given-names></name></person-group><article-title>Molecular aspects of ATP sensitive K+ channels in the cardiovascular system and K+ channel openers</article-title><source>Pharmacol Ther</source><year>2000</year><volume>85</volume><fpage>39</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10674713</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Shibasaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>466</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11984590</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>RP</given-names></name><name><surname>Laurent</surname><given-names>GJ</given-names></name><name><surname>Bishop</surname><given-names>JE</given-names></name></person-group><article-title>Collagen deposition and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors</article-title><source>Eur J Cell Biol</source><year>1995</year><volume>68</volume><fpage>330</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8603686</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruel</surname><given-names>A</given-names></name></person-group><article-title>Oxlund Biosynthetic growth hormone increase the collagen deposition rate in rat aorta and heart</article-title><source>Eur J Endocrinol</source><year>1995</year><volume>132</volume><fpage>195</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7858738</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buerke</surname><given-names>M</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name><name><surname>Skurk</surname><given-names>C</given-names></name><name><surname>Nuss</surname><given-names>C</given-names></name><name><surname>Tomaselli</surname><given-names>K</given-names></name><name><surname>Lefer</surname><given-names>AM</given-names></name></person-group><article-title>Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>8031</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">7644533</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Overexpression of insulin-like growth factor-I in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress and cardiac hypertrophy</article-title><source>J Clin Invest</source><year>1997</year><volume>100</volume><fpage>1991</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9329962</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timsit</surname><given-names>J</given-names></name><name><surname>Riou</surname><given-names>B</given-names></name><name><surname>Bertherat</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle</article-title><source>J Clin Invest</source><year>1990</year><volume>86</volume><fpage>507</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">2143510</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Ishiguro</surname><given-names>Y</given-names></name><name><surname>Stromer</surname><given-names>H</given-names></name><etal/></person-group><article-title>Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca<sup>2+</sup> through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles</article-title><source>Circ Res</source><year>1998</year><volume>83</volume><fpage>50</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9670918</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayoux</surname><given-names>E</given-names></name><name><surname>Ventura-Clapier</surname><given-names>R</given-names></name><name><surname>Timsit</surname><given-names>J</given-names></name><name><surname>Behar-Cohen</surname><given-names>F</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Mercadier</surname><given-names>JJ</given-names></name></person-group><article-title>Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion</article-title><source>Circ Res</source><year>1993</year><volume>72</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">8417847</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J</given-names></name></person-group><article-title>Short-term administration of insulin-like growth factor (IGF-1) does not induce myocardial IGF-1 resistance</article-title><source>Growth Horm IGF Res</source><year>2002</year><volume>12</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12162997</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Best</surname><given-names>PM</given-names></name></person-group><article-title>Decreased transient outward K<sup>+</sup> current in ventricular myocytes from acromegalic rats</article-title><source>Am J Physiol</source><year>1991</year><volume>260</volume><fpage>935</fpage><lpage>42</lpage></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solem</surname><given-names>ML</given-names></name><name><surname>Thomas</surname><given-names>AP</given-names></name></person-group><article-title>Modulation of cardiac Ca<sup>2+</sup> channels by IGF-1</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>252</volume><fpage>151</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9813161</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname><given-names>M</given-names></name><name><surname>Weinberg</surname><given-names>EO</given-names></name><name><surname>Batunek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>127</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9884389</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houck</surname><given-names>Wv</given-names></name><name><surname>Pan</surname><given-names>LC</given-names></name><name><surname>Kribbs</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>2003</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10556227</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huchard</surname><given-names>H</given-names></name></person-group><article-title>Anatomie pathologique, lesions et trouble cardiovasculaires de l&#x02019;acomegalie</article-title><source>J Praticiens</source><year>1895</year><volume>9</volume><fpage>249</fpage><lpage>51</lpage></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penney</surname><given-names>DG</given-names></name><name><surname>Dunbar Jr</surname><given-names>JC</given-names></name><name><surname>Baylerian</surname><given-names>MS</given-names></name></person-group><article-title>Cardiomegaly and hemodynamics in rats with a transplantable growth hormone-secreting tumor</article-title><source>Cardiovasc Res</source><year>1985</year><volume>19</volume><fpage>270</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3158390</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>SA</given-names></name><name><surname>Buttrick</surname><given-names>P</given-names></name><name><surname>Malhotra</surname><given-names>A</given-names></name><name><surname>Melmed</surname><given-names>S</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name></person-group><article-title>Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat</article-title><source>J Mol Cell Cardiol</source><year>1990</year><volume>22</volume><fpage>429</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">2143788</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prysor-Jones</surname><given-names>RA</given-names></name><name><surname>Jenkins</surname><given-names>JS</given-names></name></person-group><article-title>Effect of excessive secretion of growth hormone on tissues of the rat, with particular reference to the heart and skeletal muscle</article-title><source>J Endocrinol</source><year>1980</year><volume>85</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">7391725</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>PL</given-names></name><name><surname>Siegel</surname><given-names>RJ</given-names></name><name><surname>Melmed</surname><given-names>S</given-names></name><name><surname>Sherman</surname><given-names>CT</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name></person-group><article-title>Cardiac morphology in rats with growth hormone-producing tumours</article-title><source>J Mol Cell Cardiol</source><year>1985</year><volume>17</volume><fpage>805</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">2931534</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>HM</given-names></name><name><surname>Simpson</surname><given-names>HE</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name></person-group><article-title>The gigantism produced in normal rats by injection of pituitary growth hormone</article-title><source>Growth</source><year>1948</year><volume>12</volume><fpage>15</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">18871176</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beznak</surname><given-names>M</given-names></name></person-group><article-title>The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone</article-title><source>J Physiol (London)</source><year>1954</year><volume>124</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">13163867</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacc&#x000e0;</surname><given-names>L</given-names></name><name><surname>Napoli</surname><given-names>R</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name></person-group><article-title>Growth hormone, acromegaly, and heart failure: an intricate triangulation</article-title><source>Clin Endocrinol</source><year>2003</year><volume>59</volume><fpage>660</fpage><lpage>71</lpage></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuesen</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>SE</given-names></name><name><surname>Weeke</surname><given-names>J</given-names></name><name><surname>Orskov</surname><given-names>H</given-names></name><name><surname>Henningsen</surname><given-names>D</given-names></name></person-group><article-title>A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients?</article-title><source>Acta Med Scand</source><year>1988</year><volume>223</volume><fpage>337</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">3369314</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Biondi</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cardiovascular effects of short-terms growth hormone hypersecretion</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>179</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">10634384</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>JB</given-names></name><name><surname>Kerber</surname><given-names>RE</given-names></name><name><surname>Sherman</surname><given-names>BM</given-names></name><name><surname>Marcus</surname><given-names>ML</given-names></name><name><surname>Ehrhardt</surname><given-names>JC</given-names></name></person-group><article-title>Cardiac function in acromegaly</article-title><source>Circulation</source><year>1977</year><volume>56</volume><fpage>863</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">144034</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mather</surname><given-names>HM</given-names></name><name><surname>Boyd</surname><given-names>MJ</given-names></name><name><surname>Jenkins</surname><given-names>JS</given-names></name></person-group><article-title>Heart size and function in acromegaly</article-title><source>Br Heart J</source><year>1979</year><volume>41</volume><fpage>697</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">157147</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smallridge</surname><given-names>RC</given-names></name><name><surname>Rajfer</surname><given-names>S</given-names></name><name><surname>Davia</surname><given-names>J</given-names></name><name><surname>Schaaf</surname><given-names>M</given-names></name></person-group><article-title>Acromegaly and the heart. An echocardiographic study</article-title><source>Am J Med</source><year>1979</year><volume>66</volume><fpage>22</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">154293</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Sabatini</surname><given-names>D</given-names></name><etal/></person-group><article-title>Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study</article-title><source>Eur Heart J</source><year>1993</year><volume>14</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8432287</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Ferone</surname><given-names>D</given-names></name><name><surname>Marzullo</surname><given-names>P</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name></person-group><article-title>Systemic complications of acromegaly epidemiology, pathogenesis and management</article-title><source>Endocr Rev</source><year>2004</year><volume>25</volume><fpage>102</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">14769829</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Berggren</surname><given-names>A</given-names></name><name><surname>Longobardi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Supraphysiological doses of GH induce rapid changes in cardiac morphology and function</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>1654</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11932297</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Sabatini</surname><given-names>D</given-names></name><etal/></person-group><article-title>Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans</article-title><source>Eur Heart J</source><year>1997</year><volume>18</volume><fpage>340</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9043851</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoni</surname><given-names>PD</given-names></name><name><surname>Morandi</surname><given-names>G</given-names></name></person-group><article-title>Impaired left ventricular diastolic in acromegaly: an echocardiographic study</article-title><source>Acta Cardiol</source><year>1985</year><volume>42</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">3494364</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morvan</surname><given-names>D</given-names></name><name><surname>Komajda</surname><given-names>M</given-names></name><name><surname>Grimaldi</surname><given-names>A</given-names></name><name><surname>Turpin</surname><given-names>G</given-names></name><name><surname>Grosgogeat</surname><given-names>Y</given-names></name></person-group><article-title>Cardiac hypertrophy and function in asymptomatic acromegaly</article-title><source>Eur Heart J</source><year>1991</year><volume>12</volume><fpage>666</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">1830550</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impaired cardiac performance is a distinct feature of uncomplicated acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>1994</year><volume>79</volume><fpage>441</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8045960</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lie</surname><given-names>JT</given-names></name><name><surname>Grossman</surname><given-names>SJ</given-names></name></person-group><article-title>Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients</article-title><source>Am Heart J</source><year>1980</year><volume>100</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">6446234</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahaly</surname><given-names>G</given-names></name><name><surname>Stover</surname><given-names>C</given-names></name><name><surname>Beyer</surname><given-names>J</given-names></name><name><surname>Mohr-Kahaly</surname><given-names>S</given-names></name></person-group><article-title>Relation of endocrine and cardiac findings in acromegalics</article-title><source>J Endocrinol Invest</source><year>1992</year><volume>15</volume><fpage>13</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1532809</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name><name><surname>Caregaro</surname><given-names>L</given-names></name><name><surname>Giordano</surname><given-names>R</given-names></name><name><surname>Lauro</surname><given-names>S</given-names></name></person-group><article-title>Dysrhythmias and sudden death in acromegalic heart disease. A clinicopathologic study</article-title><source>Chest</source><year>1977</year><volume>72</volume><fpage>495</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">198185</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>BL</given-names></name><name><surname>Bruch</surname><given-names>C</given-names></name><name><surname>Saller</surname><given-names>B</given-names></name><etal/></person-group><article-title>Occurrence of left ventricular late potentials in patients active acromegaly</article-title><source>Clin Endocrinol</source><year>2001</year><volume>55</volume><fpage>201</fpage><lpage>7</lpage></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name></person-group><article-title>Are patients with acromegaly at risk for dysrhythmias?</article-title><source>Clin Endocrinol</source><year>2001</year><volume>55</volume><fpage>305</fpage><lpage>6</lpage></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Heuvel</surname><given-names>PACMB</given-names></name><name><surname>Elbers</surname><given-names>HRJ</given-names></name><name><surname>Plokker</surname><given-names>HWM</given-names></name><name><surname>Bruschke</surname><given-names>VG</given-names></name></person-group><article-title>Myocardial involvement in acromegaly</article-title><source>Int J Cardiol</source><year>1984</year><volume>6</volume><fpage>550</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6490214</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Chimenti</surname><given-names>C</given-names></name><name><surname>Setoguchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cell death in acromegalic cardiomyopathy</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>1426</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10086965</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passa</surname><given-names>P</given-names></name><name><surname>Masquet</surname><given-names>C</given-names></name><name><surname>Cophignon</surname><given-names>J</given-names></name><name><surname>Gourgon</surname><given-names>R</given-names></name><name><surname>Bouvrain</surname><given-names>Y</given-names></name></person-group><article-title>Le coeur dans l&#x02019;acromegalie. Etude hemodynamique</article-title><source>Arch Mal Coeur Vaiss</source><year>1973</year><volume>66</volume><fpage>1517</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">4210260</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuesen</surname><given-names>L</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Sorensen</surname><given-names>KE</given-names></name><name><surname>Jorgensen</surname><given-names>JOL</given-names></name><name><surname>Orskov</surname><given-names>H</given-names></name><name><surname>Henningsen</surname><given-names>P</given-names></name></person-group><article-title>Increased myocardial contractility following growth hormone administration in normal man</article-title><source>Dan Med Bull</source><year>1988</year><volume>35</volume><fpage>193</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2896102</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Losa</surname><given-names>M</given-names></name><name><surname>von Werder</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Manelli</surname><given-names>F</given-names></name></person-group><source>Growth hormone and the heart. The heart in acromegaly</source><year>2001</year><publisher-loc>Boston</publisher-loc><publisher-name>Kluwer Academic Publishers</publisher-name><fpage>33</fpage><lpage>43</lpage></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Loon</surname><given-names>GR</given-names></name></person-group><article-title>Abnormal plasma catecholamine responses in acromegalics</article-title><source>J Clin Endocrinol Metab</source><year>1979</year><volume>48</volume><fpage>784</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">372207</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sverrisdottir</surname><given-names>YB</given-names></name><name><surname>Elam</surname><given-names>M</given-names></name><name><surname>Herlitz</surname><given-names>H</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name><name><surname>Johannsson</surname><given-names>G</given-names></name></person-group><article-title>Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><fpage>1881</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9626113</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capaldo</surname><given-names>B</given-names></name><name><surname>Lembo</surname><given-names>G</given-names></name><name><surname>Rendina</surname><given-names>V</given-names></name><etal/></person-group><article-title>Sympathetic deactivation by growth hormone in patients with dilated cardiomyopathy</article-title><source>Eur Heart J</source><year>1998</year><volume>19</volume><fpage>623</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9597412</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capaldo</surname><given-names>B</given-names></name><name><surname>Lembo</surname><given-names>G</given-names></name><name><surname>Rendina</surname><given-names>V</given-names></name><etal/></person-group><article-title>Muscle sympathetic nerve activity in patients with acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>3203</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10999809</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondanelli</surname><given-names>M</given-names></name><name><surname>Ambrosio</surname><given-names>MR</given-names></name><name><surname>Franceschetti</surname><given-names>P</given-names></name><name><surname>Margutti</surname><given-names>A</given-names></name><name><surname>Trasforini</surname><given-names>G</given-names></name><name><surname>Degli Uberti</surname><given-names>EC</given-names></name></person-group><article-title>Diurnal rhythm of plasma catecholamines in acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>2458</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">10404821</pub-id></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>J</given-names></name><name><surname>Moller</surname><given-names>N</given-names></name><name><surname>Frandsen</surname><given-names>E</given-names></name><name><surname>Wolthers</surname><given-names>T</given-names></name><name><surname>Jorgensen</surname><given-names>JO</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name></person-group><article-title>Blockade of the renin-angiotensin-aldosterone system prevents growth hormone induced fluid retention in humans</article-title><source>Am J Physiol</source><year>1997</year><volume>272</volume><fpage>803</fpage><lpage>8</lpage></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCaa</surname><given-names>RE</given-names></name><name><surname>Montalvo</surname><given-names>JM</given-names></name><name><surname>McCaa</surname><given-names>CS</given-names></name></person-group><article-title>Role of growth hormone in the regulation of aldosterone biosynthesis</article-title><source>J Clin Endocrinol Metab</source><year>1978</year><volume>46</volume><fpage>247</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">220275</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalberg</surname><given-names>BE</given-names></name><name><surname>Ottoson</surname><given-names>AM</given-names></name></person-group><article-title>Acromegaly and hypertension: role of the renin-angiotensin-aldosterone system</article-title><source>Acta Endocrinol</source><year>1982</year><volume>100</volume><fpage>581</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7124280</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leri</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Overexpression of insulin-like growth factor-I attenuates the myocytes renin-angiotensin system in transgenic mice</article-title><source>Circ Res</source><year>1999</year><volume>84</volume><fpage>752</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10205143</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Remme</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>709</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10471456</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>M</given-names></name><name><surname>Faber</surname><given-names>J</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name><name><surname>Kistorp</surname><given-names>C</given-names></name><name><surname>Kristensen</surname><given-names>L&#x000d8;</given-names></name></person-group><article-title>N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances</article-title><source>Clin Endocrinol (Oxf)</source><year>2007</year><volume>66</volume><fpage>619</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">17492947</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>MC</given-names></name><name><surname>Kenneth</surname><given-names>AF</given-names></name><name><surname>Alexander</surname><given-names>RW</given-names></name><name><surname>De Lafontaine</surname><given-names>P</given-names></name></person-group><article-title>Induction of cardiac insulin-like growth factor I gene expression in pressure overload hypertrophy</article-title><source>Am J Med Sci</source><year>1993</year><volume>306</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">8362894</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isgaard</surname><given-names>J</given-names></name><name><surname>Wahlander</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>MA</given-names></name><name><surname>Friberg</surname><given-names>P</given-names></name></person-group><article-title>Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts</article-title><source>Hypertension</source><year>1994</year><volume>23</volume><fpage>884</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8206622</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>AD</given-names></name><name><surname>Hill</surname><given-names>DM</given-names></name><name><surname>Lowy</surname><given-names>C</given-names></name><name><surname>Fraser</surname><given-names>TR</given-names></name></person-group><article-title>Mortality in acromegaly</article-title><source>Q J Med</source><year>1971</year><volume>39</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">5427331</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swearingen</surname><given-names>B</given-names></name><name><surname>Barker</surname><given-names>FG</given-names></name><name><surname>Katznelson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><fpage>3419</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9768641</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokgozoglu</surname><given-names>SL</given-names></name><name><surname>Erbas</surname><given-names>T</given-names></name><name><surname>Aytemir</surname><given-names>K</given-names></name><name><surname>Akalin</surname><given-names>S</given-names></name><name><surname>Kes</surname><given-names>S</given-names></name><name><surname>Oram</surname><given-names>E</given-names></name></person-group><article-title>Effects of octreotide on left ventricular mass in acromegaly</article-title><source>Am J Cardiol</source><year>1994</year><volume>74</volume><fpage>1072</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7977053</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>J</given-names></name><name><surname>Rodriguez-Puras</surname><given-names>MJ</given-names></name><name><surname>Leal-Cerro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acromegalic cardiomyopathy improves after treatment with increasing doses of octreotide</article-title><source>J Endocrinol Invest</source><year>1991</year><volume>14</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">2045621</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merola</surname><given-names>B</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Colao</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in patients with acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>1993</year><volume>77</volume><fpage>790</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8370700</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><name><surname>Marzullo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9920056</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><name><surname>Marzullo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>1551</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11297582</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldelli</surname><given-names>R</given-names></name><name><surname>Ferretti</surname><given-names>E</given-names></name><name><surname>Jaffrain-Rea</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Cardiac effects of slow-release lanreotide, a slow release somatostatin analog, in acromegalic patients</article-title><source>J Clin Endocrin Metab</source><year>1999</year><volume>84</volume><fpage>527</fpage><lpage>32</lpage></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Marzullo</surname><given-names>P</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide</article-title><source>Clin Endocrinol</source><year>2003</year><volume>58</volume><fpage>169</fpage><lpage>76</lpage></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanson</surname><given-names>P</given-names></name><name><surname>Timsit</surname><given-names>J</given-names></name><name><surname>Masquet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cardiovascular effects of the somatostatin analog octreotide in acromegaly</article-title><source>Ann Intern Med</source><year>1990</year><volume>113</volume><fpage>921</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2240917</pub-id></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludens</surname><given-names>JH</given-names></name><name><surname>Back</surname><given-names>RR</given-names></name><name><surname>Williamson</surname><given-names>HE</given-names></name></person-group><article-title>Characteristics of the antinatriuretic action of growth hormone</article-title><source>Proc Soc Exp Biol Med</source><year>1969</year><volume>130</volume><fpage>1156</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">5779993</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iida</surname><given-names>K</given-names></name><name><surname>Koide</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Follow-up study of the heart in acromegaly: pre- and post-operative evaluation</article-title><source>Jnp J Med</source><year>1990</year><volume>29</volume><fpage>22</fpage><lpage>6</lpage></element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>MS</given-names></name><name><surname>Barkan</surname><given-names>AL</given-names></name><name><surname>Buda</surname><given-names>AJ</given-names></name></person-group><article-title>Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion</article-title><source>Ann Intern Med</source><year>1992</year><volume>117</volume><fpage>719</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">1416573</pub-id></element-citation></ref><ref id="R143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Marzullo</surname><given-names>P</given-names></name><name><surname>Ferone</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>86</volume><fpage>32</fpage><lpage>40</lpage></element-citation></ref><ref id="R144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahi</surname><given-names>M</given-names></name><name><surname>Beshyah</surname><given-names>SA</given-names></name><name><surname>Hackett</surname><given-names>D</given-names></name><name><surname>Sharp</surname><given-names>PS</given-names></name><name><surname>Johnston</surname><given-names>DG</given-names></name><name><surname>Foale</surname><given-names>RA</given-names></name></person-group><article-title>Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality</article-title><source>Br Heart J</source><year>1992</year><volume>67</volume><fpage>92</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1739534</pub-id></element-citation></ref><ref id="R145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Marzullo</surname><given-names>P</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name></person-group><article-title>Growth hormone and the heart</article-title><source>Clin Endocrinol (Oxf)</source><year>2001</year><volume>54</volume><fpage>137</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11207626</pub-id></element-citation></ref><ref id="R146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beshyah</surname><given-names>SA</given-names></name><name><surname>Johnston</surname><given-names>DG</given-names></name></person-group><article-title>Cardiovascular disease and risk factors in adults with hypopituitarism</article-title><source>Clin Endocrinol</source><year>1999</year><volume>50</volume><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="R147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>F</given-names></name><name><surname>Cuneo</surname><given-names>RC</given-names></name><name><surname>Hesp</surname><given-names>R</given-names></name><name><surname>Sonksen</surname><given-names>PH</given-names></name></person-group><article-title>The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency</article-title><source>N Engl J Med</source><year>1989</year><volume>321</volume><fpage>1797</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">2687691</pub-id></element-citation></ref><ref id="R148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuneo</surname><given-names>RC</given-names></name><name><surname>Salomon</surname><given-names>F</given-names></name><name><surname>McGauley</surname><given-names>GA</given-names></name><name><surname>Sonksen</surname><given-names>PH</given-names></name></person-group><article-title>The growth hormone deficiency syndrome in adults</article-title><source>Clin Endocrinol (Oxf)</source><year>1992</year><volume>37</volume><fpage>387</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">1486686</pub-id></element-citation></ref><ref id="R149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname><given-names>M</given-names></name><name><surname>Verhovec</surname><given-names>R</given-names></name><name><surname>Zizek</surname><given-names>B</given-names></name><name><surname>Prezelj</surname><given-names>J</given-names></name><name><surname>Poredos</surname><given-names>P</given-names></name><name><surname>Clayton</surname><given-names>RN</given-names></name></person-group><article-title>Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>453</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10022400</pub-id></element-citation></ref><ref id="R150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markussis</surname><given-names>V</given-names></name><name><surname>Beshyah</surname><given-names>SA</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Sharp</surname><given-names>P</given-names></name><name><surname>Nicolaides</surname><given-names>AN</given-names></name><name><surname>Johnston</surname><given-names>DG</given-names></name></person-group><article-title>Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults</article-title><source>Lancet</source><year>1992</year><volume>340</volume><fpage>1188</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">1359261</pub-id></element-citation></ref><ref id="R151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capaldo</surname><given-names>B</given-names></name><name><surname>Patti</surname><given-names>L</given-names></name><name><surname>Oliviero</surname><given-names>U</given-names></name><etal/></person-group><article-title>Increased arterial intima-media thickness in childhood-onset growth hormone deficiency</article-title><source>J Clin Endocrinol Metab</source><year>1997</year><volume>82</volume><fpage>1378</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9141519</pub-id></element-citation></ref><ref id="R152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borson-Chazot</surname><given-names>F</given-names></name><name><surname>Serusclat</surname><given-names>A</given-names></name><name><surname>Kalfallah</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Decrease in carotid intima-media thickness after 1 year growth hormone (GH) treatment in adults with GH deficiency</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>1329</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10199774</pub-id></element-citation></ref><ref id="R153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>H</given-names></name><name><surname>Gordienko</surname><given-names>DV</given-names></name><name><surname>Tonshoff</surname><given-names>B</given-names></name><name><surname>Gelato</surname><given-names>MC</given-names></name><name><surname>Goligorsky</surname><given-names>MS</given-names></name></person-group><article-title>Direct demonstration of insulin-like growth factor I induced nitric oxide production by endothelial cells</article-title><source>Kidney Int</source><year>1994</year><volume>45</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">7513035</pub-id></element-citation></ref><ref id="R154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boger</surname><given-names>RH</given-names></name><name><surname>Skamira</surname><given-names>C</given-names></name><name><surname>Bode-Boger</surname><given-names>SM</given-names></name><name><surname>Brabant</surname><given-names>C</given-names></name><name><surname>Von Zur Muhlen</surname><given-names>A</given-names></name><name><surname>Frolich</surname><given-names>JC</given-names></name></person-group><article-title>Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency: a double blind placebo controlled study</article-title><source>J Clin Invest</source><year>1996</year><volume>98</volume><fpage>2706</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">8981915</pub-id></element-citation></ref><ref id="R155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>G</given-names></name><name><surname>Carella</surname><given-names>C</given-names></name><name><surname>Fazio</surname><given-names>S</given-names></name><etal/></person-group><article-title>Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses</article-title><source>J Clin Endocrinol Metab</source><year>1993</year><volume>77</volume><fpage>1671</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8263158</pub-id></element-citation></ref><ref id="R156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merola</surname><given-names>B</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Colao</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency</article-title><source>J Clin Endocrinol Metab</source><year>1993</year><volume>77</volume><fpage>1658</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">8263155</pub-id></element-citation></ref><ref id="R157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><name><surname>Merola</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impaired cardiac performance in growth hormone deficient adults and its improvement after growth hormone replacement</article-title><source>Am J Physiol</source><year>1994</year><volume>267</volume><fpage>219</fpage><lpage>25</lpage></element-citation></ref><ref id="R158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longobardi</surname><given-names>S</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><name><surname>Merola</surname><given-names>B</given-names></name><etal/></person-group><article-title>Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency</article-title><source>Clin Endocrinol</source><year>1998</year><volume>48</volume><fpage>137</fpage><lpage>43</lpage></element-citation></ref><ref id="R159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuesen</surname><given-names>L</given-names></name><name><surname>Jorgensen</surname><given-names>JOL</given-names></name><name><surname>Muller</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Short and long-term cardiovascular effects of growth hormone deficient adults</article-title><source>Clin Endocrinol</source><year>1994</year><volume>41</volume><fpage>615</fpage><lpage>50</lpage></element-citation></ref><ref id="R160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valcavi</surname><given-names>R</given-names></name><name><surname>Gaddi</surname><given-names>O</given-names></name><name><surname>Zini</surname><given-names>M</given-names></name><name><surname>Iavicoli</surname><given-names>M</given-names></name><name><surname>Mellino</surname><given-names>U</given-names></name><name><surname>Portioli</surname><given-names>I</given-names></name></person-group><article-title>Cardiac performance and mass in adult with hypopituitarism: effects of one year of growth treatment</article-title><source>J Clin Endocrinol Metab</source><year>1995</year><volume>80</volume><fpage>659</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">7852533</pub-id></element-citation></ref><ref id="R161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannsson</surname><given-names>G</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name><name><surname>Andersson</surname><given-names>B</given-names></name><name><surname>Isgaard</surname><given-names>J</given-names></name><name><surname>Caidahl</surname><given-names>K</given-names></name></person-group><article-title>Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults: preliminary data in a small group of patients</article-title><source>Clin Endocrinol</source><year>1996</year><volume>45</volume><fpage>305</fpage><lpage>14</lpage></element-citation></ref><ref id="R162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuneo</surname><given-names>RC</given-names></name><name><surname>Salomon</surname><given-names>F</given-names></name><name><surname>Wiles</surname><given-names>CM</given-names></name><name><surname>Hesp</surname><given-names>R</given-names></name><name><surname>Sonksen</surname><given-names>PH</given-names></name></person-group><article-title>Growth hormone treatment in growth hormone deficient adults. I. Effects on muscle mass and strength</article-title><source>J Appl Physiol</source><year>1991</year><volume>70</volume><fpage>688</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">2022560</pub-id></element-citation></ref><ref id="R163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuneo</surname><given-names>RC</given-names></name><name><surname>Salomon</surname><given-names>F</given-names></name><name><surname>Wiles</surname><given-names>CM</given-names></name><name><surname>Hesp</surname><given-names>R</given-names></name><name><surname>Sonksen</surname><given-names>PH</given-names></name></person-group><article-title>Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance</article-title><source>J Appl Physiol</source><year>1991</year><volume>70</volume><fpage>695</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2022561</pub-id></element-citation></ref><ref id="R164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impaired cardiac performance in elderly patients with growth hormone deficiency</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>85</volume><fpage>3950</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10566633</pub-id></element-citation></ref><ref id="R165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Cuocolo</surname><given-names>A et al</given-names></name></person-group><article-title>The severity of GH deficiency (GHD) correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><issue>12</issue><fpage>5998</fpage><lpage>6004</lpage><pub-id pub-id-type="pmid">15579750</pub-id></element-citation></ref><ref id="R166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maison</surname><given-names>P</given-names></name><name><surname>Chanson</surname><given-names>P</given-names></name></person-group><article-title>Cardiac effects of growth hormone in adults with growth hormone deficiency</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>2648</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">14623813</pub-id></element-citation></ref><ref id="R167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuocolo</surname><given-names>A</given-names></name><name><surname>Nicolai</surname><given-names>E</given-names></name><name><surname>Colao</surname><given-names>A</given-names></name><etal/></person-group><article-title>Improved left ventricular function after growth hormone replacement in patients with hypopituitarism assessment with radionuclide angiography</article-title><source>Eur J Nucl Med</source><year>1996</year><volume>23</volume><fpage>390</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8612658</pub-id></element-citation></ref><ref id="R168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>1874</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">11344175</pub-id></element-citation></ref><ref id="R169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannsson</surname><given-names>G</given-names></name><name><surname>Albertsson-Wikland</surname><given-names>K</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name></person-group><article-title>Discontinuation of growth hormone (GH) treatment metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>4516</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">10599711</pub-id></element-citation></ref><ref id="R170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beshyah</surname><given-names>SA</given-names></name><name><surname>Shahi</surname><given-names>M</given-names></name><name><surname>Skinner</surname><given-names>E</given-names></name><name><surname>Sharp</surname><given-names>P</given-names></name><name><surname>Foale</surname><given-names>R</given-names></name><name><surname>Johnston</surname><given-names>DG</given-names></name></person-group><article-title>Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults</article-title><source>Eur J Endocrinol</source><year>1994</year><volume>130</volume><fpage>451</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8180671</pub-id></element-citation></ref><ref id="R171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>JOL</given-names></name><name><surname>Pedersen</surname><given-names>SA</given-names></name><name><surname>Thuesen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Beneficial effects of growth hormone treatment in GH-deficient adults</article-title><source>Lancet</source><year>1989</year><volume>1</volume><fpage>1221</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2566779</pub-id></element-citation></ref><ref id="R172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Salerno</surname><given-names>M</given-names></name><name><surname>Spinelli</surname><given-names>L</given-names></name><name><surname>Orio F</surname><given-names>Jr</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name></person-group><article-title>The cardiovascular risk of growth hormone-deficient adolescents</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>3650</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12161490</pub-id></element-citation></ref><ref id="R173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maison</surname><given-names>P</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name><name><surname>Nicoue-Beglah</surname><given-names>M</given-names></name><name><surname>Haddad</surname><given-names>N</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Chanson</surname><given-names>P</given-names></name></person-group><article-title>Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo controlled trials</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>2192</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15126541</pub-id></element-citation></ref><ref id="R174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrisoulidou</surname><given-names>A</given-names></name><name><surname>Beshyah</surname><given-names>SA</given-names></name><name><surname>Rutherford</surname><given-names>O</given-names></name><etal/></person-group><article-title>Effects of 7 years of growth hormone replacement therapy in hypopituitary adults</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>3762</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11061536</pub-id></element-citation></ref><ref id="R175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Rota</surname><given-names>F</given-names></name><etal/></person-group><article-title>Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>2056</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15671089</pub-id></element-citation></ref><ref id="R176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colao</surname><given-names>A</given-names></name><name><surname>Di Somma</surname><given-names>C</given-names></name><name><surname>Cuocolo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a 2-year open, prospective study in young adult men and women with severe GH deficiency</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>5146</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15985481</pub-id></element-citation></ref><ref id="R177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castagnino</surname><given-names>HE</given-names></name><name><surname>Toranzos</surname><given-names>FA</given-names></name><name><surname>Milei</surname><given-names>J</given-names></name><etal/></person-group><article-title>Preservation of the myocardial collagen framework by human growth hormone in experimental infarctions and reduction in the incidence of ventricular aneurysms</article-title><source>Int J Cardiol</source><year>1992</year><volume>35</volume><fpage>101</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">1563865</pub-id></element-citation></ref><ref id="R178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambler</surname><given-names>GR</given-names></name><name><surname>Johnston</surname><given-names>BM</given-names></name><name><surname>Maxwell</surname><given-names>L</given-names></name><name><surname>Gavin</surname><given-names>JB</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name></person-group><article-title>Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I</article-title><source>Cardiovasc Res</source><year>1993</year><volume>27</volume><issue>7</issue><fpage>1368</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">8252601</pub-id></element-citation></ref><ref id="R179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Hiroe</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes</article-title><source>Circulation</source><year>1993</year><volume>87</volume><fpage>1715</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7683979</pub-id></element-citation></ref><ref id="R180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>RL</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Miraliakbar</surname><given-names>HR</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name><name><surname>Ross J</surname><given-names>Jr</given-names></name></person-group><article-title>Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><issue>2</issue><fpage>619</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">7860746</pub-id></element-citation></ref><ref id="R181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Grossman</surname><given-names>JD</given-names></name><name><surname>Napoli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>1997</year><volume>29</volume><fpage>1109</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">9120168</pub-id></element-citation></ref><ref id="R182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Gillett</surname><given-names>N</given-names></name><name><surname>Clark</surname><given-names>RG</given-names></name><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>Paoni</surname><given-names>NF</given-names></name></person-group><article-title>Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition</article-title><source>J Cardiovasc Pharmacol</source><year>1995</year><volume>26</volume><issue>3</issue><fpage>420</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8583784</pub-id></element-citation></ref><ref id="R183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>RL</given-names></name><name><surname>McKirnan</surname><given-names>MD</given-names></name><name><surname>Gim</surname><given-names>RD</given-names></name><name><surname>Clark</surname><given-names>RG</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name><name><surname>Ross J</surname><given-names>Jr</given-names></name></person-group><article-title>Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat</article-title><source>Circulation</source><year>1996</year><volume>93</volume><issue>12</issue><fpage>2188</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">8925588</pub-id></element-citation></ref><ref id="R184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Bunting</surname><given-names>S</given-names></name><name><surname>Gillet</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name></person-group><article-title>Growth hormone improves cardiac performance in experimental heart failure</article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>262</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7600659</pub-id></element-citation></ref><ref id="R185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Isgaard</surname><given-names>J</given-names></name><name><surname>Monti</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Growth hormone prolongs survival in experimental postinfarction heart failure</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><fpage>2154</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12821240</pub-id></element-citation></ref><ref id="R186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Str&#x000f6;mer</surname><given-names>H</given-names></name><name><surname>Katz</surname><given-names>SE</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Moses</surname><given-names>AC</given-names></name><name><surname>Morgan</surname><given-names>JP</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name></person-group><article-title>Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined <italic>in vivo</italic> and <italic>in vitro</italic> evaluation</article-title><source>Circulation</source><year>1996</year><volume>93</volume><issue>4</issue><fpage>800</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8641010</pub-id></element-citation></ref><ref id="R187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Griese</surname><given-names>DP</given-names></name><name><surname>Riegger</surname><given-names>GAJ</given-names></name><name><surname>Kromer</surname><given-names>E</given-names></name></person-group><article-title>Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction</article-title><source>Cardiovas Res</source><year>1998</year><volume>40</volume><fpage>297</fpage><lpage>306</lpage></element-citation></ref><ref id="R188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isgaard</surname><given-names>J</given-names></name><name><surname>Kujacic</surname><given-names>V</given-names></name><name><surname>Jennische</surname><given-names>E</given-names></name><etal/></person-group><article-title>Growth hormone improves cardiac function in rats with experimental myocardial infarction</article-title><source>Eur J Clin Invest</source><year>1997</year><volume>27</volume><issue>6</issue><fpage>517</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">9229233</pub-id></element-citation></ref><ref id="R189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross J</surname><given-names>Jr</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name></person-group><article-title>The role of hypertrophy and growth factors in heart failure</article-title><source>J Card Fail</source><year>1996</year><volume>2</volume><issue>4 Suppl</issue><fpage>121</fpage><lpage>8</lpage></element-citation></ref><ref id="R190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houck</surname><given-names>WV</given-names></name><name><surname>Pan</surname><given-names>LC</given-names></name><name><surname>Kribbs</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>2003</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10556227</pub-id></element-citation></ref><ref id="R191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinugawa</surname><given-names>S</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><etal/></person-group><article-title>Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes</article-title><source>Cardiovasc Res</source><year>1999</year><volume>43</volume><fpage>157</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10536700</pub-id></element-citation></ref><ref id="R192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname><given-names>U</given-names></name><name><surname>Kupferschmid</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>D</given-names></name><name><surname>Pentz</surname><given-names>S</given-names></name></person-group><article-title>Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes <italic>in vitro</italic></article-title><source>Basic Res Cardiol</source><year>1988</year><volume>83</volume><fpage>647</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">3066340</pub-id></element-citation></ref><ref id="R193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freestone</surname><given-names>NS</given-names></name><name><surname>Ribaric</surname><given-names>S</given-names></name><name><surname>Mason</surname><given-names>WT</given-names></name></person-group><article-title>The effect of insulin-like growth factor-1 on adult rat cardiac contractility</article-title><source>Mol Cell Biochem</source><year>1996</year><volume>163-164</volume><fpage>223</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8974061</pub-id></element-citation></ref><ref id="R194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stromer</surname><given-names>H</given-names></name><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><name><surname>Morgan</surname><given-names>JP</given-names></name></person-group><article-title>Exogenously administered growth hormone and insulin-like growth factor-i alter intracellular Ca<sup>2+</sup> handling and enhance cardiac performance <italic>in vitro</italic> evaluation in the isolated isovolumic buffer-perfused rat heart</article-title><source>Circ Res</source><year>1996</year><volume>79</volume><fpage>227</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">8755999</pub-id></element-citation></ref><ref id="R195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Lewinski</surname><given-names>D</given-names></name><name><surname>Vo&#x000df;</surname><given-names>K</given-names></name><name><surname>H&#x000fc;lsmann</surname><given-names>S</given-names></name><name><surname>K&#x000f6;gler</surname><given-names>H</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name></person-group><article-title>Insulin-like growth factor-1 exerts Ca<sup>2+</sup>-dependent positive inotropic effects in failing human myocardium</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><fpage>169</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">12574144</pub-id></element-citation></ref><ref id="R196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Juanatey</surname><given-names>JR</given-names></name><name><surname>Pineiro</surname><given-names>R</given-names></name><name><surname>Iglesias</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>GH prevents apoptosis in cardiomyocytes cultured <italic>in vitro</italic> through a calcineurin-dependent mechanism</article-title><source>J Endocrinol</source><year>2004</year><volume>180</volume><fpage>325</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">14765985</pub-id></element-citation></ref><ref id="R197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haunstetter</surname><given-names>A</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name></person-group><article-title>Apoptosis. Basic mechanisms and implications for cardiovascular disease</article-title><source>Circ Res</source><year>1998</year><volume>82</volume><fpage>1111</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">9633912</pub-id></element-citation></ref><ref id="R198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>PM</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name></person-group><article-title>Apoptosis and heart failure: a critical review of the literature</article-title><source>Circ Res</source><year>2000</year><volume>86</volume><fpage>1107</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10850960</pub-id></element-citation></ref><ref id="R199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baixeras</surname><given-names>E</given-names></name><name><surname>Jeay</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>PA</given-names></name><name><surname>Postel-Vinay</surname><given-names>MC</given-names></name></person-group><article-title>The proliferative and antiapoptotic actions of growth hormone and insulin-like growth factor-1 are mediated through distinct signaling pathways in the Pro-B Ba/F3 cell line</article-title><source>Endocrinology</source><year>2001</year><volume>142</volume><fpage>2968</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">11416018</pub-id></element-citation></ref><ref id="R200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeay</surname><given-names>S</given-names></name><name><surname>Sonenshein</surname><given-names>GE</given-names></name><name><surname>Postel-Vinay</surname><given-names>MC</given-names></name><name><surname>Baixeras</surname><given-names>E</given-names></name></person-group><article-title>Growth hormone prevents apoptosis through activation of nuclear factor-kB in interleukin-3-dependent Ba/F3 cell line</article-title><source>Mol Endocrinol</source><year>2000</year><volume>14</volume><fpage>650</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10809229</pub-id></element-citation></ref><ref id="R201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeay</surname><given-names>S</given-names></name><name><surname>Sonenshein</surname><given-names>GE</given-names></name><name><surname>Kelly</surname><given-names>PA</given-names></name><name><surname>Postel-Vinay</surname><given-names>MC</given-names></name><name><surname>Baixeras</surname><given-names>E</given-names></name></person-group><article-title>Growth hormone exerts antiapoptotic and proliferative effects through two different pathways involving nuclear factor-kB and phosphatidylinositol 3-kinase</article-title><source>Endocrinolgy</source><year>2001</year><volume>142</volume><fpage>147</fpage><lpage>56</lpage></element-citation></ref><ref id="R202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuneo</surname><given-names>RC</given-names></name><name><surname>Wilmshurst</surname><given-names>P</given-names></name><name><surname>Lowy</surname><given-names>C</given-names></name><name><surname>McGauley</surname><given-names>G</given-names></name><name><surname>Sonksen</surname><given-names>PH</given-names></name></person-group><article-title>Cardiac failure responding to growth hormone</article-title><source>Lancet</source><year>1989</year><volume>1</volume><fpage>838</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2564917</pub-id></element-citation></ref><ref id="R203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Perrone</surname><given-names>GA</given-names></name><name><surname>Gentiloni</surname><given-names>N</given-names></name><name><surname>Russo</surname><given-names>MA</given-names></name></person-group><article-title>Reversible dilated cardiomyopathy due to growth hormone deficiency</article-title><source>Am J Clin Pathol</source><year>1992</year><volume>97</volume><fpage>503</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">1553916</pub-id></element-citation></ref><ref id="R204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Sabatini</surname><given-names>D</given-names></name><name><surname>Capaldo</surname><given-names>B</given-names></name><etal/></person-group><article-title>A preliminary study of growth hormone in the treatment of dilated cardiomyopathy</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>809</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">8596546</pub-id></element-citation></ref><ref id="R205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterziel</surname><given-names>KJ</given-names></name><name><surname>Strohm</surname><given-names>O</given-names></name><name><surname>Schuler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1233</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9643742</pub-id></element-citation></ref><ref id="R206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isgaard</surname><given-names>J</given-names></name><name><surname>Bergh</surname><given-names>CH</given-names></name><name><surname>Caidahl</surname><given-names>K</given-names></name><name><surname>Lomsky</surname><given-names>M</given-names></name><name><surname>Hjalmarson</surname><given-names>A</given-names></name><name><surname>Bengtsson</surname><given-names>BA</given-names></name></person-group><article-title>A placebo-controlled study of growth hormone in patients with congestive heart failure</article-title><source>Eur Heart J</source><year>1998</year><volume>19</volume><fpage>1704</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9857924</pub-id></element-citation></ref><ref id="R207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genth-Zotz</surname><given-names>S</given-names></name><name><surname>Zotz</surname><given-names>R</given-names></name><name><surname>Geil</surname><given-names>S</given-names></name><name><surname>Voigtl&#x000e4;nder</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Darius</surname><given-names>H</given-names></name></person-group><article-title>Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>18</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9884373</pub-id></element-citation></ref><ref id="R208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spallarossa</surname><given-names>P</given-names></name><name><surname>Rossettin</surname><given-names>P</given-names></name><name><surname>Minuto</surname><given-names>F</given-names></name><etal/></person-group><article-title>Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease</article-title><source>Am J Cardiol</source><year>1999</year><volume>84</volume><fpage>430</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10468082</pub-id></element-citation></ref><ref id="R209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrot</surname><given-names>A</given-names></name><name><surname>Ranke</surname><given-names>MB</given-names></name><name><surname>Dietz</surname><given-names>R</given-names></name><name><surname>Osterziel</surname><given-names>KJ</given-names></name></person-group><article-title>Growth hormone treatment in dilated cardiomyopathy</article-title><source>J Card Surg</source><year>2001</year><volume>16</volume><fpage>127</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">11766830</pub-id></element-citation></ref><ref id="R210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Gentiloni</surname><given-names>N</given-names></name><name><surname>Russo</surname><given-names>MA</given-names></name></person-group><article-title>Growth hormone in the treatment of dilated cardiomyopathy</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>672</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8692248</pub-id></element-citation></ref><ref id="R211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jose</surname><given-names>VJ</given-names></name><name><surname>Zechariah</surname><given-names>TU</given-names></name><name><surname>George</surname><given-names>P</given-names></name><name><surname>Jonathan</surname><given-names>V</given-names></name></person-group><article-title>Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study</article-title><source>Indian Heart J</source><year>1999</year><volume>51</volume><fpage>183</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10407547</pub-id></element-citation></ref><ref id="R212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acevedo</surname><given-names>M</given-names></name><name><surname>Corbalan</surname><given-names>R</given-names></name><name><surname>Chamorro</surname><given-names>G</given-names></name><etal/></person-group><article-title>Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status</article-title><source>Int J Cardiol</source><year>2003</year><volume>87</volume><fpage>185</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12559539</pub-id></element-citation></ref><ref id="R213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittadini</surname><given-names>A</given-names></name><name><surname>Comi</surname><given-names>IL</given-names></name><name><surname>Longobardi</surname><given-names>S</given-names></name><etal/></person-group><article-title>A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular distrophies</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><fpage>664</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12657225</pub-id></element-citation></ref><ref id="R214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname><given-names>JW</given-names></name><name><surname>Janssen</surname><given-names>YJ</given-names></name><name><surname>Lamb</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>4638</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11600518</pub-id></element-citation></ref><ref id="R215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Parissis</surname><given-names>JT</given-names></name><name><surname>Georgiadis</surname><given-names>M</given-names></name><etal/></person-group><article-title>Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy</article-title><source>Am Heart J</source><year>2002</year><volume>144</volume><fpage>359</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12177657</pub-id></element-citation></ref><ref id="R216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parissis</surname><given-names>JT</given-names></name><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Karatzas</surname><given-names>D</given-names></name><name><surname>Paraskevaidis</surname><given-names>J</given-names></name><name><surname>Livanis</surname><given-names>E</given-names></name><name><surname>Kremastinos</surname><given-names>D</given-names></name></person-group><article-title>Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2005</year><volume>12</volume><fpage>164</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15785303</pub-id></element-citation></ref><ref id="R217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Parissis</surname><given-names>JT</given-names></name><name><surname>Paraskevaidis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><fpage>2186</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">14659770</pub-id></element-citation></ref><ref id="R218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Palmieri</surname><given-names>EA</given-names></name><name><surname>Affuso</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>4218</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17698902</pub-id></element-citation></ref><ref id="R219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Corvoisier</surname><given-names>P</given-names></name><name><surname>Hittinger</surname><given-names>L</given-names></name><name><surname>Chanson</surname><given-names>P</given-names></name><name><surname>Montagne</surname><given-names>O</given-names></name><name><surname>Macquin-Mavier</surname><given-names>I</given-names></name><name><surname>Maison</surname><given-names>P</given-names></name></person-group><article-title>Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>180</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17062772</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. (1)</label><caption><p>Growth hormone (GH), by increasing left ventricle mass and myocardial contractility, and decreasing wall stress and vascular resistance, enhances cardiac performance.</p></caption><graphic xlink:href="CCR-5-203_F1"/></fig><fig id="F2" position="float"><label>Fig. (2)</label><caption><p>The effect of GH on VO2max and on the chronotropic index increased, and end-systolic wall stress and isovolumic relaxation time were reduced. Placebo did not affect any of the above parameters.</p></caption><graphic xlink:href="CCR-5-203_F2"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of Clinical Studies on GH Treatment in Chronic Heart Failure</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">References</th><th rowspan="1" colspan="1">StudyDesign</th><th rowspan="1" colspan="1">Patients Enrolled</th><th rowspan="1" colspan="1">Age (mean &#x000b1; SD)</th><th rowspan="1" colspan="1">Target dose (IU/wk)</th><th rowspan="1" colspan="1">IGF-1 Increase (%)</th><th rowspan="1" colspan="1">Therapy Duration (Months)</th><th rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fazio S<sub>b</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Open</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">46 &#x000b1; 9</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">105.1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, IVS, PW, LVM, EDD, ESD, ESWS, EF, E/A, IRT, SVR, ED, NYHA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Frustaci A<sub>g</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Open</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">32 &#x000b1; 8.1</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">IVS, EDD, EF</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Isgaard J<sub>d</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">60 &#x000b1; 11.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25 IU/kg&#x000b7;wk up to 28</td><td align="center" valign="middle" rowspan="1" colspan="1">137.1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, IVS, PW, LVM, EDD, ESD, ESWS, EF, E/A, IRT, SVR, ED, NYHA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Osterziel K<sub>c</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">54 &#x000b1; 10</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">78.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, IVS, PW, LVM, EDD, ESWS, EF, SVR, NYHA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Genth-Zotz S<sub>e</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Open</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">55 &#x000b1; 9</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">110.1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, PW, EDD, ESD, EF, SVR, VO<sub>2</sub>max, ED, NYHA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jose VJ<sub>h</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Open</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">IVS, PW, EDD, ESD, EF, ED, NYHA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spallarossa P<sub>f</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">62.1 &#x000b1; 8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14 IU/kg&#x000b7;wk</td><td align="center" valign="middle" rowspan="1" colspan="1">89</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">IVS, PW, LVM, EDD, EF, E/A, IRT, ED, NYHA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Smit JW<sub>k</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">65.5 &#x000b1; 8.5</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">36.7</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, LVM, EF, ESWS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Napoli R<sub>a</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">54.5&#x000b1;11.3</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">85.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, VO<sub>2</sub>max</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acevedo M<sub>i</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">57.7 &#x000b1; 4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.245 IU/kg&#x000b7;wk</td><td align="center" valign="middle" rowspan="1" colspan="1">40.1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">EF, VO<sub>2</sub>max</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adamopoulos S<sub>m</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Cross- over</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">50 &#x000b1; 13.8</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">PW, ESWS, VO<sub>2</sub>max</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cittadini A<sub>j</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">38.9&#x000b1;10.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21 IU/kg&#x000b7;wk</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HR, IVS, PW, EF, E/A, SVR, ESWS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fazio S<sub>n</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind placebo controlled</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">PL:57&#x000b1;11<break/>GH:54&#x000b1;10</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">101&#x000b1;18</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">MAP, VE, VO<sub>2</sub>max, RER, VE-VCOslope, Breathing reserve, chronotropic index, Mechanical workefficiency, CI, IRT, ESD, ESWS, EF, SVR, RWT</td></tr></tbody></table><table-wrap-foot><fn id="T1FN1"><p>Adapted from: Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 2007; 92: 180-5 (203).</p></fn><fn id="T1FN2"><p>CI, cardiac index; E/A, ratio between early and late mitral diastolic flow; ED, exercise duration; EDD, LV end-diastolic diameter; EF, ejection fraction; ESD, LV end-systolic diameter; ESWS, end-systolic wall stress; GH, growth hormone; HR, heart rate; IRT, isovolumetric relaxation time; IU, international unit; IVS, interventricular septum; kg, kilogram; LVM, LV mass; MAP, mean arterial pressure; NA, Not available; NYHA, New York Heart Association; PL, placebo; PW, posterior wall; RER, respiratory exchange ratio; RWT, relative wall thickness; SVR, systemic vascular resistance VE-VCO slope, minute ventilation-carbon dioxide production slope; VO2 max, maximal peak oxygen uptake; wk, week; a:[<xref ref-type="bibr" rid="R68">68</xref>]; b:[<xref ref-type="bibr" rid="R90">90</xref>]; c:[<xref ref-type="bibr" rid="R205">205</xref>];  d:[<xref ref-type="bibr" rid="R206">206</xref>];  e:[<xref ref-type="bibr" rid="R207">207</xref>];  f:[<xref ref-type="bibr" rid="R208">208</xref>]; g:[<xref ref-type="bibr" rid="R210">210</xref>]; h:[<xref ref-type="bibr" rid="R211">211</xref>]; i:[<xref ref-type="bibr" rid="R212">212</xref>]; j:[<xref ref-type="bibr" rid="R213">213</xref>]; k:[<xref ref-type="bibr" rid="R214">214</xref>]; m:[<xref ref-type="bibr" rid="R216">216</xref>]; n:[<xref ref-type="bibr" rid="R218">218</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article>